Mechanisms of Ect2 Regulation in Cytokinesis and Oncogenesis by Cook, Danielle
Mechanisms of Ect2 Regulation in Cytokinesis and Oncogenesis 
Danielle R. Cook 
A dissertation submitted to the faculty of the University of North Carolina at 
Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy in the Eshelman School of Pharmacy Division of Chemical Biology 
and Medicinal Chemistry 
Chapel Hill, NC 
2013 
 
 
 
 
 
 
Approved by 
Channing J. Der PhD,  
Michael B. Jarstfer PhD, 
Mohanish Deshmukh PhD, 
Lee M. Graves PhD, 
Klaus M. Hahn PhD 
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2013 
Danielle R. Cook 
ALL RIGHTS RESERVE 
 
 iii 
Abstract 
 
DANIELLE R. COOK: Mechanisms of Ect2 Regulation in Cytokinesis and 
Oncogenesis 
(Under the direction of Channing Der) 
 
Ect2 is a member of the human Dbl family of guanine nucleotide exchange 
factors and are activators of Rho family small GTPases (RhoA, Rac1 and 
Cdc42). Ect2 was identified originally as an oncogene. However, the truncated 
and activated Ect2 variant identified was due to a DNA manipulation artifact and 
to date has not been found in human cancers. Ect2 has also been shown to be 
essential for mammalian cell cytokinesis in established cell culture models. My 
studies involve further evaluation of Ect2 in normal and neoplastic cell biology. 
First, to further evaluate a role for Ect2 in cytokinesis, we evaluated the 
consequences of an Ect2 deficiency in normal cells. Our studies showed that an 
Ect2 deficiency in primary mouse embryo fibroblasts (MEFs) caused a defect in 
cytokinesis, migration, and altered cell morphology in vitro. In vivo loss of Ect2 in 
a mouse caused embryonic lethality. Thus, Ect2 is essential for normal 
development; a characteristic that has only been found in two other Dbl family 
RhoGEFs of 25 members evaluated. Second, in a gene array analysis of 
colorectal cancer (CRC), we identified ECT2 transcriptional overexpression and 
further analysis of oncomine database also confirmed the transcriptional 
overexpression of Ect but was not due gene amplification. We then found an 
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increase in Ect2 protein expression in primary and metastatic CRC tumors and 
cell lines. Depletion of endogenous Ect2 by shRNA in CRC cell lines caused a 
reduction in anchorage-independent growth and Matrigel invasion without a 
corresponding defect in cytokinesis. Analyses of Ect2 protein expression in a 
CRC tumor microarray (N=149) found Ect2 protein overexpression in tumor 
tissue, but surprisingly, the ratio of cytoplasmic to nuclear Ect2 correlated with 
improved patient survival. This finding contrasted with earlier studies that 
suggested that the mislocalization of the normally nuclear restricted Ect2 to the 
cytoplasm was important for Ect2 to function as an oncogene.  
With this unexpected finding, I then utilizing my validated MEF and CRC 
cell line models to assess the structural and functional requirements for Ect2 
support of normal cell cytokinesis and cancer cell growth. Ect2 is a large 
multidomain protein. In addition to tandem Dbl homology RhoGEF catalytic and 
pleckstrin homology regulatory domains found in all Dbl RhoGEFs (>70 human 
members), Ect2 contains N-terminal tandem BRCT domains not found in any 
other RhoGEFs and two nuclear localization sequences that promote Ect2 
nuclear localization. Using missense mutants of full length Ect2 with impaired 
domain/motif function, I found that the BRCT domains are dispensable for Ect2-
dependent CRC growth but necessary for normal cell cytokinesis. In contrast, 
disruption of the Ect2 nuclear localization sequences abolished the ability of Ect2 
to support both normal cell cytokinesis and CRC tumor cell growth. The former 
observation was unexpected since there is no nuclear envelope during 
cytokinesis. The latter finding was also surprising, contrasting with previous 
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findings in lung cancer, but consistent with our findings in CRC tumor tissue 
microarray. In particular, we found that the cytoplasmic localized, constitutively 
activated Ect2 that potently causes growth transformation of NIH 3T3 mouse 
fibroblasts was deleterious for CRC growth. In summary, my studies may resolve 
a paradox in the field, to explain why the originally truncated and activated Ect2 
identified in mouse fibroblasts have not been found in human cancer. 
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Chapter 1 Introduction 
Superfamily of Ras GTPases 
The RAS gene was originally identified in two different cancer causing 
virus originally discovered in rat, hence the name Ras (rat sarcoma) [1] and is the 
founding member of the Ras Superfamily of small GTPases containing over 150 
members [2, 3]. Members of this superfamily are divided into five major branches 
based on sequence and functional similarities: Ras, Rho, Rab, Ran, and Arf. 
(Figure 1-1) However, variations in structure, post-translational modifications, 
subcellular locations, and effectors proteins allow GTPases to function as 
modulators of complex and diverse range of cellular processes [4]. 
 
Figure 1-1 Small GTPase  
Left panel: Ras Superfamily Right panel: Human Rho GTPases (20 members; RhoA, Rac1, and 
Cdc42 are characterized the best)  
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Rho GTPases 
Rho family proteins (20 human members) comprise a major branch of the 
Ras superfamily of small GTPases, with RhoA, Rac1 and Cdc42 the most 
extensively studied and characterized. (Figure 1-1) Rho GTPases specifically 
regulate actin organization, cell motility, polarity, growth, survival and gene 
transcription [5]. Rho GTPases are binary switches that cycle between an active 
GTP-bound and an inactive GDP-bound state [6]. Rho-specific guanine 
nucleotide exchange factors (RhoGEFs) accelerate the intrinsic exchange activity 
of Rho GTPases to stimulate formation of Rho-GTP. Rho-specific GTPase 
activating proteins (RhoGAPs) stimulate the intrinsic hydrolysis activity of Rho 
GTPases, resulting in the inactive GDP-bound state [7]. Rho-specific guanine 
nucleotide-dissociation inhibitors (GDIs) comprise a third class of regulatory 
proteins. RhoGDIs bind Rho GTPases in a GDP bound state and also extract 
and sequester Rho GTPases from the cell membrane where Rho GTPases can 
be activated [8]. (Figure 1-2)  
 18 
 
Figure 1-2 Rho GTPase Signaling [9] 
The discovery of RhoGEFs: diverse in numbers and structure 
The first RhoGEF was identified initially as an oncogene in mammalian 
cells. Using the NIH 3T3 mouse fibroblast focus formation assay that led to the 
discovery of mutant Ras in human cancer, analysis of genomic DNA isolated 
from a human diffuse B-cell lymphoma resulted in the discovery of the DBL 
oncogene that encoded an N-terminally truncated protein [10]. Dbl was 
subsequently shown to catalyze the exchange activity of Cdc42 [11]. Additional 
NIH 3T3 focus formation and related assays identified Dbl-related proteins, in 
particular Vav and Ect2. That RhoGEFs were discovered initially as oncoproteins 
provided the first suggestion that Rho GTPases may also have a function in 
oncogenesis. 
Regulators+and+eﬀectors+of+Rho+GTPases+
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Dbl and the Dbl-related proteins all share a ~200 amino acid catalytic Dbl 
homology (DH; also called RhoGEF) and an immediately adjacent regulatory 
~100 amino acid pleckstrin homology (PH) domain [12]. Additional RhoGEFs with 
this tandem DH-PH domain structure were identified by genetic and biochemical 
approaches and by in silico database searches. There are 72 human Dbl family 
RhoGEFs, with conserved orthologs found in all vertebrate species and in 
invertebrates, including Drosophila, C. elegans, S. cerevisiae and S. pombe. 
Beyond their shared DH-PH domains, Dbl RhoGEFs diverge significantly in their 
flanking N- and C-terminal sequences, which commonly contain a diversity 
protein-protein interaction domains and motifs involved in regulating intrinsic 
RhoGEF catalytic activity, determining subcellular localization or facilitating 
complex formation with other proteins. (Figure 1-3) 
Humans also possess a second structurally distinct but biochemically 
similar class of RhoGEFs, the dedicator of cytokinesis or DOCK family (11 
human members) [13]. DOCK RhoGEFs are characterized by conserved Dock-
homology region-2 (DHR2) catalytic domain with no sequence homology to DH 
domains. Although plant species possess Rho-like GTPases (Rho of plants; Rop) 
[14], and are regulated by RhoGAPs homologous to mammalian RhoGAPs [15], 
they lack either Dbl or DOCK RhoGEFs and instead RopGEFs possess a 
structurally distinct plant-specific Rop nucleotide exchanger (PRONE) catalytic 
domain [16]. Finally, although there are no Rho orthologs in prokaryotes, 
pathogenic bacteria possess effector proteins that regulate the function of their 
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mammalian host Rho GTPases, in particular, proteins that mimic the function of 
mammalian RhoGEFs [17, 18].  
 
Figure 1-3 Dbl family RhoGEFs 
Ect2: Epithelial Cell Transforming Sequence 2 
In 1993, human Ect2 was originally discovered as an oncogene that 
transformed NIH 3T3 cells [19]. However, the Ect2 protein found to transform 
fibroblast was a truncated version of the full-length protein that is not found in 
nature. (Figure 1-4) The best-characterized function of Ect2 is for its role in 
normal cell cytokinesis, however there are studies supporting a non cell-cycle 
function in cancer.  
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Figure 1-4 Discovery of Ect2 in NIH 3T3  
The transforming Ect2 was truncated and constitutively activated protein not found in nature or 
cancer [19] 
Ect2 in Cytokinesis 
Cytokinesis is the physical division of one cell into two and is the final step 
in mitosis or meiosis, a cell division process that is tightly regulated by many 
proteins and is essential in proliferation or development respectively. (Figure 1-5) 
Cytokinesis requires coordinated actions of the cytoskeleton, membrane 
systems, and other cell cycle machinery, which are precisely controlled spatially 
and temporally. During late anaphase the actomyosin ring is formed and then 
starts to ingresses during telophase giving rise to the cleavage furrow and by late 
telophase the cleavage furrow is fully ingressed forming an intracellular bridge, 
called the midbody [20]. SNARE-dependent membrane fusion steps promote the 
abscission event needed to complete cytokinesis [21]. Cytoskeleton 
rearrangements are required during the formation of the actomyosin ring and 
then ingression until abscission is complete is dependent on Rho GTPase 
localization and activity [22-26].    
Ect2 originally identified as an  
activated oncogene 
Mouse keratinocyte DNA 
NIH 3T3 focus-formation assay 
Truncated Ect2 
Ect2 
FL found in normal & cancer cells 
Miki et al. (1993) Nature 362:462  
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Figure 1-5 Cytokinesis[20, 21, 23] 
 
Before the human Ect2 was characterized, mutations in Pebble (Pbl), the 
Drosophila ortholog of Ect2, caused a block in cytokinesis [27, 28].  After Ect2 
was discovered, functional studies of Pbl in Drosophila established a critical role 
in cytokinesis. At the onset of cytokinesis, Pbl is associated with the cleavage 
furrow where it activates Rho1 to initiate assembly of the contractile ring and 
promote cytokinesis [29]. Similarly, Let-21 the C. elegans ortholog of Ect2 is 
required for formation of the cleavage furrow [30]. Further evidence of Ect2 
function in cytokinesis was demonstrated by the interference of mammalian Ect2 
function through the expression of a dominant negative ECT2 allele, 
microinjection of an Ect2 antibody, or Ect2 RNAi-mediated knockdown all lead to 
accumulation of multinucleated cells indicative of a failure to undergo cytokinesis 
[31, 32]. Furthermore, studies have shown that the role of Ect2 in cytokinesis is 
to activate RhoA signaling pathways as well as recruit other proteins such as 
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RacGAP1; knockdown of either RhoA or RacGAP lead to multinucleation [23, 33, 
34].   
Ect2 Domain Structure 
Ect2 is multi-domain protein with unique features not found in other 
RhoGEFs. (Figure 1-6) For example, the N-terminus of Ect2 contains a pair of 
tandem BRCA1 C-terminal (BRCT) repeats. BRCT domains are found in a large 
superfamily of ~40 onorthologous proteins that have functions in cell cycle 
checkpoints and/or in the DNA damage response [35]. BRCT domains can 
promote heterodimerization with other BRCT-containing proteins or recognize 
phosphorylated peptides. There is evidence suggesting that the second but not 
the first BRCT domain of Ect2 may function as auto-inhibitor of the DH domain 
[31, 36]. These data support a model where protein binding or modification of 
Ect2 relieves BRCT auto-inhibition, leading to reversible activation of Ect2 
RhoGEF function. There is evidence that BRCT domains found in tandem can 
cooperate to provide sequence-specific binding of phosphorylated peptides [37]. 
For example, the tandem BRCTs domains have a positive role to promote Ect2 
localization to the midbody during cytokinesis: the BRCT domains bind to Plk1-
phosphorylated MgcRacGAP31 (RacGAP1), a protein that, like Ect2, is both 
located to the midbody during cytokinesis and required for its successful 
completion [26]. 
 Another rare feature of Ect2 is that it contains two nuclear localization 
sequences (NLS) and is located in the cell’s nucleus during interphase. Net1 is 
the only other RhoGEF found in the nucleus and was found recently that Net1 is 
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dispensable for mouse development (Jeffrey Frost, personal communication). 
The N-terminal truncated forms of Ect2 lacking the NLS motifs are able to 
transform NIH 3T3 as well as full-length Ect2 containing missense mutation that 
abolish NLS function, suggesting that mislocalization to the cytoplasm is 
important for Ect2 to drive growth transformation. Furthermore, cytoplasmic Ect2 
has been linked to Rac1 activation and cellular transformation [38]. 
 
Figure 1-6 Ect2 multi-domain RhoGEF 
   
The C-terminus of Ect2 comprises the DH-PH domains contained in all 
Dbl family RhoGEFs. While it is known that the DH domain is required for GEF 
activity the function of the PH domain remains to be investigated [12]. 
Furthermore, the there remains considerable confusion regarding which Rho 
GTPases are targets of Ect2 and whether distinct Rho GTPases facilitate Ect2 
control of cytokinesis versus growth transformation. Most studies have attributed 
Ect2 regulation of cytokinesis to its activation of RhoA [23, 24, 39-42], whereas 
transformation of lung tumor cells by full length (FL) Ect2 has been linked to 
Rac1 activation [38]. However, for transformation of NIH 3T3 mouse fibroblast 
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cells, all three Rho GTPases were necessary for transformation by an N-
terminally truncated Ect2 (ΔN-Ect2) [36, 43]. Usually RhoGEF substrate 
specificity is dictated solely by the DH domain [12], however the GTPase 
specificity of Vav, was influenced by its flanking sequences [44]. However, for 
Ect2 it is unknown if the DH domain alone or flanking sequences determine 
GTPases specificity.  
Following the tandem DH-PH domains, the C-terminus is composed of 
highly conserved sequence of approximately 363 amino acids that lacks any 
known domains or motifs. (Figure 1-7) However, this C-terminal sequence of 
Ect2 was found to be required for ΔN-Ect2 to cause growth transformation of NIH 
3T3 mouse fibroblasts and was shown to alter the Rho GTPases activated in vivo 
[43]. Recently, TEK- and D-box (destruction box) domains have been described 
in the C-terminus and shown to be necessary for full length Ect2 degradation 
following mitosis by an ubiquitin ligase, APC/Cdh1 (anaphase promoting 
complex) [45, 46]. Destruction box (D-box) is a conserved motif, RXXL, found in 
a majority of APC substrates [47], while a TEK-box motif is found in ubiquitin and 
several human APC substrates; it was identified to play a role in substrate 
binding and poly-ubiquitination [48].  
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Figure 1-7 Ect2 C-terminus 
RhoGEFs and development 
The combined number of human Dbl and DOCK RhoGEFs greatly exceed 
the number of Rho GTPases, suggesting apparent redundancy in RhoGEF 
function. This is particularly striking for RhoA, where at least 25 Dbl RhoGEFs 
can activate this single GTPase. With six of 20 human Rho GTPases 
constitutively active and not believed to be regulated by RhoGEFs [49], the 
apparent redundancy in RhoGEFs is even more significant.  
One approach to evaluate the apparent redundancy of RhoGEFs has 
been the generation of mice deficient in one or more RhoGEFs, which 
additionally addresses their involvement in development. The role of at least 24 
Dbl family RhoGEFs in mouse development have been evaluated, with only four 
(Sos1, Trio, AKAP13 and Ect2) found to be essential for mouse development 
[50-53]. However, since these proteins possess other functions independent of 
their RhoGEF functions, it is not clear that the embryonic lethality seen is due to 
the loss of the RhoGEF function. Sos1 and Trio both have non-RhoGEF catalytic 
activities: Sos1 is also a RasGEF and Trio contains two distinct DH-PH RhoGEF 
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domains and a serine/threonine kinase domain. AKAP13 is a scaffolding protein 
with additional activities that include association with the regulatory subunit of 
protein kinase A to spatially regulate protein kinase A substrate utilization, protein 
kinase C and D isoforms, and interaction with heterotrimeric G alpha subunits. In 
contrast Ect2 has no other known catalytic function aside from its RhoGEF 
activity suggesting that Ect2 is an essential RhoGEF among a highly redundant 
family of proteins. In my studies, I determined that the requirement for Ect2 in 
development is likely due to its critical role in cytokinesis [53].  
Ect2 in development 
Recently we showed that Ect2-deficient mice are not viable [53]. Whereas 
heterozygous Ect2+/- mice showed normal development and lifespan, no Ect2-/- 
embryos were found at birth or as early as embryonic day 8.5, suggesting a 
requirement for Ect2 for either preimplantation or early postimplantation 
development. We further characterized the defect in vitro with isolated 
blastocysts at E3.5 and identified homozygous Ect2-/- blastocysts displayed 
abnormal outgrowth, indicating that Ect2 is required for peri-implantation 
development.  
The best-characterized normal function of Ect2 is its role in cytokinesis. 
Even though there are at least 25 other RhoGEFs that can active RhoA, Ect2 has 
been shown to regulate RhoA during cytokinesis, the final step in meiosis and 
mitosis. Therefore, it is likely that Ect2 is required for development because of its 
key role in cell division. Consistent with this hypothesis, a deficiency in 
MgcRacGAP (RacGAP1), which facilitates Ect2 localization during cell division, 
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also produces a similar embryonic lethality phenotype [54].  
RhoGEFs and cancer 
The three Ras proteins are the founding members of the Ras superfamily 
of small GTPases and they comprise the most commonly mutated oncoproteins 
in cancer. However, with the exception of the recently described mutational 
activation of Rac1 in melanoma [55, 56], Rho (Ras homologs) GTPases are not 
frequently mutated in human cancer. Nevertheless, there is substantial 
experimental evidence that aberrant Rho GTPase function can contribute to 
cancer cell proliferation, invasion and metastasis [57]. Rather than direct 
mutational activation, Rho GTPases are instead activated by indirect 
mechanisms in cancer. These mechanisms include altered location by GDIs, 
increased RhoGEF and/or decreased RhoGAP activity, and altered gene 
expression of Rho GTPases, RhoGEFs, RhoGAPs, and RhoGDI expression. 
Other mechanisms include alternative gene splicing such as Rac1b [58].  
Although Dbl and other RhoGEFs identified as oncoproteins were found to 
be activated by deletion of sequences, most commonly by deletion of sequences 
N-terminal to the DH domain, these altered and constitutively 
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activated RhoGEFs were not present in the original tumor DNA and instead 
arose artifactually during the DNA isolation/transfection procedure [59]. Similarly, 
other Dbl RhoGEFs identified as oncogenes also possessed rearranged 
sequences, most commonly N-terminal deletion of sequences upstream of the 
DH domain, which arose during in vitro DNA manipulation/or the transfection 
process. Surprisingly, despite their potent transforming activities when assayed 
in NIH 3T3 mouse fibroblasts, such activated Dbl RhoGEFs have not been 
identified in cancers. Instead, mechanisms that lead to the deregulated 
expression and/or activation of full length RhoGEFs have been identified. In this 
section, we summarize the findings with the Dbl RhoGEFs with the strongest 
evidence for their involvement in cancer growth. (Figure 1-8) 
Ect2 in Cancer 
Ect2 gene and/or protein overexpression has been described in 
glioblastoma [60-62], non-small cell lung cancer (NSCLC) [38], lung and 
esophageal [63], pancreatic [44] and oral cancer [64].  
The ECT2 gene is located in a region of the chromosome 3q26 which is a 
region that is frequently altered in human tumors [65]. It was found that Ect2 
overexpression was cause by gene amplification in non-small cell lung cancer 
(NSCLC) and this also correlated with copy number of the PKCι gene (PRKCI) 
[38]. Regulation of tumor growth and invasion of non-small cell lung cancer was 
through mislocalization of Ect2 to the cytoplasm where it could bind to PKCi-Par6 
to activate Rac1 [38]. Interestingly, the role of Ect2 in NSCLC was independent 
of Ect2 normal function in cytokinesis. Depletion of Ect2 expression in NSCLC 
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did not result in any proliferation or multi-nucleation defects that are associated 
with Ect2 loss in normal cells [53]. Furthermore, this study was the first 
description of a mislocalization and activation of Rac1 mechanism mediated by 
Ect2. In my studies, I have addressed a role for altered mislocalization of Ect2 to 
the cytoplasm in driving CRC growth. 
 Another study showed that Ect2 expression correlated with poor prognosis 
of glioma patients and that in vitro Ect2 was important for proliferation, migration, 
and invasion of giloma cells [61]. However, the depletion of Ect2 expression in 
giloma tumor cell lines showed an increase in multinucleation, characteristic of a 
defect in cytokinesis. Therefore, the decrease in proliferation, migration and 
invasion could be cause by the inability for cells to complete mitosis. Another 
study found that Ect2 was overexpressed in glioblastoma and showed that Ect2 
was required to mediate the invasive behavior in glioblastoma in vitro by siRNA 
knockdown [62].  
To search for novel biomarkers that may be improved diagnosis, 
prognosis, and therapeutic intervention of CRC, a recent meta-analysis of 
publicly available data from GenBank identified ECT2 as one of nines gene 
significantly elevated levels in CRC tissues compared to normal tissues [66]. 
However, whether Ect2 protein expression is elevated and is a driver for CRC 
growth was not determined. Independently, our microarray gene expression 
studies identified ECT2 overexpression in CRC. CRC is the number two cause of 
cancer deaths for men and women in the US, with 50,830 deaths expected in 
2013 [67] Hence, there remains a dire need for new therapies for this deadly 
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cancer. In my dissertation research, I have evaluated the role of Ect2 in normal 
and neoplastic growth, with a focus on the role and mechanism by which 
aberrant Ect2 expression may drive CRC growth. 
Colorectal Cancer (CRC) 
Colorectal cancer (CRC) is a major cause of cancer morbidity and 
mortality, with ~150,000 U.S. residents diagnosed annually with CRC, and 
approximately one-third of CRC patients die from the disease [67]. The lifetime 
risk of CRC (from 2005-2009) in the United States is ~5%, and the average age 
at diagnosis is 69 years [68]. Risk factors for CRC development include, age, 
diet, and inherited and/or somatic mutations [69]. 
  The prevailing model for CRC tumorigenesis based on the accumulation 
of genetic mutations, each defining a different step in the adenoma–carcinoma 
sequence [70](Figure 1-9). In this sequence, the first hit that associated with 
adenomatous polyps is mutation and/or loss of the APC gene. K-ras mutations 
are found in ~50% of colorectal cancers and are thought to be relatively early 
events that correlate histologically with early to late adenomas. There is evidence 
to suggest that TP53 (p53) mutations occur more frequently in high-grade 
dysplastic polyps; these mutations are associated the transition from adenoma to 
carcinoma [71]. Further mutations in TGF-βIIR, SMAD4, BAX, and/or mutations 
in mismatch repair genes (e.g. hMLH1, hMSH2) have all been identified factors 
in the development and progression of CRC [70, 72].  
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Figure 1-9 Genetic model of colorectal cancer 
Colorectal cancer progresses through accumulation of genetic mutations [70, 73].  
 
Specific Aims 
Based on the importance of Rho GTPases activity in cellular behavior; I 
sought to determine Ect2 specific effect in normal and tumor biology. I used 
structural and functional full-length Ect2 mutants to determine critical Ect2 
elements required for cytokinesis and oncogene.  
The next two chapters of my dissertation address my original three aims. 
Aim I, determine the role of Ect2 overexpression in the invasive and metastatic 
growth properties of colorectal cancer. (Chapter 3) Aim II, determine the 
structural and functional requirements of Ect2 activity in normal cell cytokinesis. 
(Chapter 2 & 3) Aim III, determine the structural and functional requirements of 
Ect2 that confer an oncogenic phenotype. (Chapter 3) I conclude my 
dissertations with final thoughts on my studies and future directions. (Chapter 4) 
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Chapter 2  Characterization of Ect2 in development and normal cell 
function1 
Overview 
Ect2 is a member of the human Dbl family of guanine nucleotide exchange 
factors (RhoGEFs) that serve as activators of Rho family small GTPases. 
Although Ect2 is one of at least 25 RhoGEFs that can activate the RhoA small 
GTPase, cell culture studies using established cell lines determined that Ect2 is 
essential for mammalian cell cytokinesis and proliferation. To address the 
function of Ect2 in normal mammalian development, we performed gene 
targeting to generate Ect2 knockout mice. The heterozygous Ect2+/- mice showed 
normal development and lifespan, indicating that Ect2 haplodeficiency was not 
deleterious for development or growth. In contrast, Ect2-/- embryos were not 
found at birth or post-implantation stages. Ect2-/- blastocysts were recovered at 
embryonic day 3.5 but did not give rise to viable outgrowths in culture, indicating 
that Ect2 is required for peri-implantation development. To further assess the 
importance of Ect2 in normal cell physiology, we isolated primary fibroblasts from 
Ect2fl/fl embryos (MEFs) and ablated Ect2 using adenoviral delivery of Cre 
recombinase. We observed a significant increase in multinucleated cells and 
accumulation of cells in G2/M phase, consistent with a role for Ect2 in 
                                            
1 Chapter adapted from published paper: “The ect2 rho Guanine nucleotide exchange factor is essential for early mouse 
development and normal cell cytokinesis and migration” Cook, D. R., Solski, P. A., Bultman, S. J., Kauselmann, G., 
Schoor, M., Kuehn, R., Friedman, L. S., Cowley, D. O., Van Dyke, T., Yeh, J. J., Johnson, L., Der, C. J. Genes and 
Cancer, 2011 
 35 
cytokinesis. Ect2 deficiency also caused enlargement of the cytoplasm and 
impaired cell migration. Finally, although Ect2-dependent activation of RhoA has 
been implicated in cytokinesis, Ect2 can also activate Rac1 and Cdc42 to cause 
growth transformation. Surprisingly, ectopic expression of constitutively activated 
RhoA, Rac1, or Cdc42, known substrates of Ect2, failed to phenocopy Ect2 and 
did not rescue the defect in cytokinesis cause by loss of Ect2. In summary, our 
results establish the unique role of Ect2 in development and normal cell 
proliferation. 
Introduction  
Rho family small GTPases are regulators of diverse cellular processes 
that include cell proliferation and survival, actin organization and cell shape, 
polarity and movement, and endocytosis and exocytosis [6, 49]. There are 20 
human Rho GTPases, with RhoA, Rac1 and Cdc42 the best-characterized 
members. Rho GTPases function as GDP-GTP regulated binary switches that 
are activated in response to extracellular stimuli. Activated Rho GTPases in turn 
associate with effectors that then stimulate cytoplasmic signaling networks [74]. 
Rho-specific guanine nucleotide exchange factors (RhoGEFs) promote GDP-
GTP exchange and formation of active Rho-GTP [12], whereas Rho-specific 
GTPase activating proteins (RhoGAPs) accelerate hydrolysis of the bound GTP 
to stimulate formation of inactive Rho-GDP [75]. 
 There are 83 human RhoGEFs, with Dbl family RhoGEFs comprising the 
largest group (69 members) [9, 12]. Dbl family RhoGEFs are characterized by a 
conserved Dbl homology (DH) catalytic domain and an adjacent C-terminal 
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pleckstrin homology (PH) regulatory domain. The DH domain may be highly or 
broadly specific for a subset of Rho GTPases. For example, Tiam1 is a specific 
activator of Rac, Asef is specific for Cdc42, whereas Vav is broadly active and 
can activate RhoA, Rac, Cdc42 and RhoG.  
The significantly greater number of RhoGEFs relative to their GTPase 
substrates suggests highly redundant mechanisms for Rho GTPase activation. 
This apparent redundancy in activators is particularly striking for RhoA, where 
there are at least 25 Dbl RhoGEFs that can activate this Rho GTPase [12]. 
However, the multiple RhoGEFs for one Rho GTPase provides mechanisms 
where a specific Rho GTPase can be activated by divergent signals, leading to 
distinct spatio-temporal patterns of activation and signaling. This divergence in 
RhoGEF regulation and function is reflected by the otherwise highly divergent 
sequences that flank the DH-PH domains [74]. RhoGEFs are generally large 
proteins (>1000 amino acids), and often contain several domains involved in their 
localization, association with other proteins, regulation of GEF catalytic activity 
and Rho GTPase effector selectivity. For example, among all human RhoGEFs, 
only Ect2 contains tandem BRCT (BRCA1 C-terminal) domains that are normally 
found in proteins (e.g., BRCA1, TP53BP1) involved in DNA damage signaling, 
repair and coordination of cell cycle checkpoints [37, 76]. The BRCT domains 
may serve to regulate the RhoGEF catalytic activity and additionally can interact 
with phosphorylated proteins that dictate Ect2 subcellular localization [31, 77, 
78].  
 37 
Ect2 is also only one of two Dbl family RhoGEFs, aside from Net1 [79], 
that exhibits a nuclear localization in interphase cells [32]. Since Rho GTPases 
are membrane-associated and/or cytoplasmic, it has been proposed that this 
nuclear localization is an inactive repository for Ect2, since disruption of nuclear 
localization activates Ect2 transforming activity [36]. However, a recent study 
found that nuclear Ect2 maybe active [80], and thus, whether nuclear Ect2 has a 
function during interphase and distinct from cytokinesis remains unresolved. The 
best-known function of Ect2 involves its requirement for cytokinesis in vitro [65, 
81]. In early mitosis (prometaphase) when the nuclear envelope is dissolved, 
Ect2 is released into the cytoplasm. As cells enter anaphase, Ect2 is recruited to 
the central spindle by the central spindlin protein complex comprised of 
Cyk4/MgcRacGAP and MKLP1/CHO1. The central spindle facilitates contractile 
ring formation, leading to cleavage furrow ingression and midbody formation. 
Ect2 is recruited to the midbody where Ect2 then activates RhoA to facilitate 
midbody abscission and completion of cytokinesis. Ectopic expression of a 
noncatalytic fragment of Ect2 that includes the BRCT domains caused inhibition 
of U-2 OS human osteosarcoma [32] or adenovirus-transformed HEK 293T 
human kidney neuronal-like [82] to complete cytokinesis, resulting in the 
accumulation of multinucleated cells. Similarly, microinjection of anti-Ect2 
antibody into HeLa human cervical carcinoma cells also inhibited cytokinesis 
[32]. Subsequent studies using transient RNA interference suppression of Ect2 
expression in HEK 293T [82] or HeLa [31, 83] cells also demonstrated a 
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requirement for Ect2 in cytokinesis in vitro. No assessment of mammalian Ect2 
function in normal cells in vitro or in vivo has been described. 
Although Ect2 was identified originally as an activated oncoprotein that 
was activated by truncation and loss of N-terminal sequences that include the 
BRCT domains and nuclear localization signals [19], no such truncated proteins 
have been detected in human cancers. Instead, recent studies have identified 
aberrant overexpression and mislocalization of full length Ect2 to the cytoplasm 
in glioblastoma and lung cancer tumor tissue and cell lines [38, 60, 62]. These 
studies used RNA interference to suppress Ect2 expression, which caused 
impaired lung tumor cell anchorage-independent growth and Matrigel invasion in 
vitro and reduced tumorigenic growth in vivo. Interestingly, in lung tumor cells, 
Ect2 suppression did not impair cytokinesis, indicating that Ect2 function in 
oncogenesis is distinct from that in cytokinesis [38]. Further support for this 
possibility was provided by the observation that constitutively activated Rac1 
could rescue the loss of endogenous Ect2 and restore lung tumor cell growth 
[38]. This finding contrasts with previous studies that found that RhoA is the 
substrate critical for Ect2-dependent cytokinesis [65, 81]. 
Previous studies of mammalian Ect2 function have been done in 
established cell line studies in vitro. To evaluate the function of Ect2 in vivo, in 
normal cells and in the context of heterogeneous tissue, we generated both 
floxed (conditional) and Δfloxed (constitutive) knockout mice to assess the 
consequences of Ect2 loss in development and normal cell proliferation. 
Constitutive loss of Ect2 causes embryonic lethality, with defective growth at the 
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late blastocyst stage. Utilizing mouse embryo fibroblasts derived from Ect2fl/fl 
conditional mice, we determined that loss of Ect2 completely impaired cell 
proliferation and migration in vitro, causing accumulation of cells in G2/M phase 
and formation of enlarged multi-nucleated cells. Surprisingly, expression of 
activated Rho GTPases failed to rescue the loss of Ect2 to restore cell 
proliferation or migration. Our observations provide further evidence for the highly 
unique function of this RhoGEF in normal cell physiology. 
Methods and Materials 
Vector construction: The targeting vector was based on a 5.3 kb 
genomic fragment from the ect2 gene encompassing exons 8 to 12 and 
surrounding sequences. This fragment, obtained from the C57Bl/6J RP23 BAC 
library, was modified by inserting the distal loxP site into intron 8 and the 
proximal loxP site including an FRT-flanked neomycin resistance gene into intron 
7. A thymidine kinase (TK) cassette was inserted at the 3’ end of the genomic 
fragment. 
Embryonic stem (ES) cell culture: The quality tested C57BL/6NTac ES 
cell line was grown on a mitotically inactivated feeder layer comprised of MEFs in 
Dulbecco’s modified eagle (DMEM) high glucose medium supplemented with 
20% fetal bovine serum (FBS; PAN Biotech GmbH) and 1200 U/ml leukemia 
inhibitory factor (Millipore; ESG 1107). One x 107 ES cells and 30 µg of linearized 
DNA targeting vector were electroporated (Biorad Gene Pulser) at 240 V and 500 
µF. Positive selection with G418 (200 µg/ml) started on day two and 
counterselection with gancyclovir (2 µM) started on day five after electroporation. 
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Resistant ES cell colonies with a distinct morphology were isolated on day eight 
after transfection and expanded in 96 well plates. Correctly recombined ES cell 
clones were identified by Southern blot analysis using external and internal 
probes and were frozen in liquid nitrogen. 
Generation of mice: The animal study protocol was approved according 
to the German Animal Welfare Act (§ 8 (1) TierSchG) by the local authority. Mice 
were kept in the animal facility at TaconicArtemis GmbH in microisolator cages 
(Techniplast Sealsave). Feed and water were available ad libitum. Light cycles 
were on a 12:12 h light:dark cycle with the light phasing starting at 06:00 h. 
Temperature and relative humidity were maintained between 21 to 23°C and 45 
to 65%, respectively. After administration of hormones, superovulated BALB/c 
females were mated with BALB/c males. Blastocysts were isolated from the 
uterus at dpc 3.5. For microinjection, blastocysts were placed in a drop of DMEM 
supplemented with 15% FBS under mineral oil. A flat tip, piezo actuated 
microinjection-pipette with an internal diameter of 12 - 15 µm was used to inject 
10 to15 targeted C57BL/6NTac ES cells into each blastocyst. After recovery, 
eight injected blastocysts were transferred to each uterine horn of 2.5 days post 
coitum, pseudopregnant NMRI females. Chimerism was measured in chimeras 
(G0) by coat color contribution of ES cells to the BALB/c host (black/white). 
Highly chimeric mice were bred to i) C57BL/6-Tg(CAG-Flpe)2Arte females 
mutant for the presence of the Flp recombinase gene or to ii) C57BL/6-
Gt(ROSA)26Sortm16(Cre)Arte females mutant for the presence of the Cre 
recombinase gene. This allowed detection of germline transmission by the 
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presence of black, strain C57BL/6, offspring (G1) and creation of i) selection 
marker deleted conditional (floxed) knockout mice or ii) constitutive knockout 
mice by Flp- or Cre-mediated removal, in one breeding step. Chimeras bred to iii) 
C57BL/6 wild-type mice resulted in germline offspring with selection marker in 
the Ect2 genomic locus described as targeted mice.  
Genotyping of mice by PCR: Genomic DNA was extracted from 1 to 2 
mm long tail tips using the NucleoSpin Tissue kit (Macherey-Nagel). Genomic 
DNA (2 µl) was analyzed by PCR protocol 1 in a final volume of 50 µl in the 
presence of 2.0 mM MgCl2, 200 µM dNTPs, 100 nM of each primer, and 2 U Taq 
DNA polymerase (Invitrogen) with the following primers: 1 = (5’-
GCACTCCAATTATGAAGCCAGAATGG-3’), 2 = (5’-
CAATATGTTGGGTAGAGAGATGGC-3’) and 3 = (5’-
TCCTCCGGGTGGACCAGAG-3’) detecting the presence of the wild-type allele 
(335 bp), targeted (413 bp), the conditional allele (413 bp) and the constitutive 
allele (498 bp). Following a denaturing step at 95°C for 5 min, 35 cycles of PCR 
were performed, each consisting of a denaturing step at 95°C for 30 s, followed 
by an annealing phase at 60°C for 30 s and an elongation step at 72°C for 1 min. 
PCR was finished by a 10 min extension step at 72°C. Amplified products were 
analyzed using 2% standard TAE agarose gels. A second PCR protocol for 
genotyping the Ectfl/fl mice used two primers: 3 = (5’- 
TCTGATCCACGTGATCATAG-3’), and 4 = (5’-CTGGCTT CATAATTGGAGTGC-
3’). A 420 bp wild-type fragment or a 520 bp mutant fragment was amplified with 
these two primers. For genotyping the blastocysts, a nested PCR protocol was 
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used. The outgrowths were scraped from the well with a micropipette tip and 
transferred to a PCR tube. The tubes were spun down and the supernatant was 
removed. The cells were resuspended in 5 µl of 400ng/µl Proteinase K/17 µM 
SDS and overlayed with mineral oil. The tubes were incubated for 1 h at 50°C, 
and then denatured at 99°C for 30 min. For the first PCR reaction, 45 µl of a PCR 
mix containing 25 pmol of external primers (5’-
CCCTCCAGGTTGAGAACTGCTACTAAG-3’ and 5’-
GCAGGCTGAGAGCAAGCCAGGAGA-3’). After amplification, 1 µl of this first 
PCR reaction was used for a second round of PCR reactions, which used PCR 
protocol 1 as described above.  
Blastocyst outgrowth analyses: Timed breedings of ect2 +/- breeding 
pairs were set up and at E3.5, blastocysts were flushed from the uterine tract 
from the females. Blastocysts were placed in 20 µl of ES cell medium (DMEM, 
15% FCS, 0.01% β-mercaptoethanol) in Nunc dish microwells (Nalgene,Palo 
Alto, CA) and grown under mineral oil in 5% CO2 incubator at 37°C. After seven 
days, the cultures were evaluated and scored for degree of outgrowth, 
photographed, and then genotyped by PCR. 
Mouse embryonic fibroblasts cultures: Ect2fl/fl mice were crossed and 
at E15.5 days embryos were isolated from the female. Embryos were rinsed with 
PBS, and the head and dark red organs were removed from the culture. The 
tissue was minced and resuspended in a solution of PBS/trypsin/EDTA and 
incubated with gentle shaking at 37°C for 30 min. The cell/tissue solution was 
gently centrifuged and the supernatant was removed and the loose pellet was 
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resuspended in DMEM supplemented with 10% FCS. This solution was then 
filtered through a cell filter and then plated onto 150 mm tissue culture plates and 
grown in a 5% CO2 incubator at 37°C. After 18 h, the medium was changed to 
fresh growth medium. MEFs were immortalized by trypsinizing the cells every 
three days at replating on a 100 mm tissue culture plate at a density for 1 X 103 
cells/ dish. For knocking out Ect2 expression in the Ectfl/fl MEFs, cells were 
infected with recombinant adenovirus expressing Cre recombinase (Ad-Cre) with 
a green fluorescent protein expressing control adenovirus (Ad-GFP) used to 
assess Cre-specific activities (Gene Transfer Vector Core, University of Iowa). 
Constructs: An expression vector for human Ect2 was generated using a 
human Ect2 cDNA sequence from an expression vector kindly provided by Dr. A. 
P. Fields (Mayo Clinic, Rochester, MN), which was subcloned into the FUGW 
lentiviral expression vector [84], a gift from Dr. Bryan Roth (University of North 
Carolina at Chapel Hill, Chapel Hill, NC). Mammalian expression vectors of wild-
type human Rho GTPases [RhoA, Rac1 and Cdc42] were constructed by ligation 
of cDNA sequences into a pBabe-puro retrovirus expression vector [85]that 
introduces an N-terminal HA epitope tag. The constitutively active [RhoA(Q63L), 
Rac1(Q61L) and Cdc42(Q61L)] and fast-cycling Rho GTPases mutants 
[RhoA(F30L), Rac1(F28L) and Cdc42(F28L)] were created using QuikChange 
site-directed mutagenesis kit (Stratagene). 
Western blot: To evaluate protein expression, four days after Cre 
infection, the MEFs were lysed, and analyzed by SDS-polyacrylamide gel 
electorphoresis and western blot analysis, with anti-Ect2 antibody (Santa Cruz 
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Biotechnology), anti-HA (Covance) and anti-β-actin (Sigma) as a loading control. 
Additionally, we utilized a second Ect2 polyclonal antibody generated against 
KLH-conjugated linear peptide corresponding to C-terminal sequences in human 
Ect2 (Millipore). 
Immunofluorescence: To visualize nuclei content, three days after Ad-
Cre-infection the MEFs were plated onto coverslips. Twenty-four h after 
attachment, coverslips were rinsed with PBS, and fixed with 2% 
paraformaldehyde in phosphate-buffered saline (PBS) for 10 min. The cells were 
stained for 5 min with 5 ng/ml 4',6-diamidino-2-phenylindole (DAPI) in PBS, 
washed 2-3 times with PBS and then mounted onto slides. The cells were 
visually analyzed for nuclei content on an Olympus BX61 upright fluorescence 
microscope. Images collected using Velocity (Perkin Elmer). To visualize 
polymerized F-actin, cells were stained with Alexa Fluor® 647 phalloidin 
(Invitrogen). 
Flow cytometry: Cells were trypsinized, washed in PBS and then fixed in 
70% ethanol and then stored at -20°C. The day prior to analysis the cells were 
washed in PBS and then stained with 0.5 ml of propidium iodine staining solution 
(1% Triton-X-100, 1 mg/ml PI, 100 mg/ml of RNAse A) overnight at 4°C. Data 
were collected on Beckman Coulter CyAn analyzer and ModFit (Becton 
Dickinson) was used for cell cycle analysis. 
Results 
Generation of Ect2 mutant mice. In order to evaluate the function of 
Ect2 in mammalian development we generated a conditional null mutation of the 
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mouse Ect2 locus by gene targeting. Our targeting strategy focused on exon 8, 
which encodes the N-terminal tandem BRCT domains, by flanking it with loxP 
sites (Figure 2-1A). Cre-mediated deletion resulted in a Δfloxed allele lacking 
exon 8 that is a null mutation based on the complete loss of Ect2 protein 
expression as we describe below. Figure 2-1A shows a schematic diagram of the 
wild-type Ect2 allele, the targeting vector, the targeted allele after homologous 
recombination, and the resulting floxed (conditional) and Δfloxed (conditional null) 
alleles. 
 
Figure 2-1 Targeted disruption of the mouse Ect2 gene produces a null mutation 
(A) Schematic diagram of the targeting vector, the wild-type allele, and the resulting Ect2 floxed 
allele (fl/fl) after FLP mediated deletion and the Ect2Δfloxed (null) allele after Cre mediated 
deletion. Numbered, black bold vertical lines represent Ect2 exons and horizontal gray bar 
represents flanking intron sequences. LoxP and FRT sites are indicated by black and grey 
triangles, respectively. PCR primers for genotype analysis are indicated by the arrows. (B) 
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Genotypic analysis of wild-type (+/+), heterozygous Δfloxed (+/-), mutant (null; mut) and floxed 
(fl/fl) DNA by PCR. Primer pair 1 and 2 produced a 334 bp wild-type fragment. Primer pair 3 and 
2 produced a 498 bp mutant fragment. Primer pair 3 and 4 produced a 535 bp fragment from the 
wild-type allele, and a 655 bp fragment from the floxed allele. Abbreviations used are: DNA 
isolated from heterozygous constitutive (Δfloxed) mice, +/- DNA; DNA isolated from wild-type 
mice, +/+ DNA; DNA isolated from homozygous conditional (floxed) mice, fl/fl DNA; detection of 
the constitutive allele, Δfloxed; detection of the conditional allele,floxed); detection of the wild-type 
allele, WT. (Data provided by Kauselmann, Schoor, Kuehn, Friedman) 
 
Peri-implantation lethality of Ect2 mutant embryos. A ubiquitous Cre 
driver was used to generate constitutive null heterozygotes. Intercrosses of these 
Ect2+/- mice failed to produce any homozygous mutants at birth among 224 
offspring, suggesting that Ect2-/- is embryonic lethal (Table 2-1). Therefore, we 
performed Ect2+/- intercrosses as timed matings and genotyped embryos at 
progressively earlier stages of development. No Ect2-/- embryos were obtained at 
embryonic days (E) 15.5, 13.5, or 8.5 (Table 2-1). These results suggested that 
Ect2 is required for either pre-implantation or early post-implantation 
development.  
Table 2-1. Genotypes of Weanlings and Embryos from Ect2 -/+ Intercrosses 
(Data provided by Solski, Bultman, Cowley, and Van Dyke) 
 Genotype 
Stage +/+ +/- -/- 
At weaning 92 132 0 
Embryos (13.5-15.5) 10 16 0 
Embryos (8.5)a 5 5 0 
a Examination of maternal uteri exhibited empty deciduas, suggesting peri-implantation 
lethality. 
 
To investigate the peri-implantation stage in more detail, we performed 
additional Ect2+/- intercrosses, isolated blastocysts at E3.5, and analyzed their 
outgrowth ex vivo [86]. Homozygous Ect2-/- blastocysts had a morphologically 
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normal trophectoderm (TE) and inner cell mass (ICM) (Figure 2-2). We cultured 
125 blastocysts for five days and then scored the resulting outgrowths and 
determined their genotypes. After this culture period, 84% of wild-type 
outgrowths and 92% of Ect2+/- outgrowths were scored as normal based on the 
presence of both TE and extensive ICMs (Figure 2-2, Table 2-2). In contrast, no 
Ect2-/- outgrowths were scored as normal. Instead, 14% of homozygous 
blastocysts failed to hatch from their zona pellucida and the remaining 86% were 
scored as abnormal based on the ICM not being viable. These results indicate 
Ect2 is required for peri-implantation development.  
Figure 2-2 Ect2-/- blastocysts display abnormal growth in vitro  
Photographs of wild-type (+/+), heterozygous (+/-), and homozygous null (-/-) blastocyst at time of 
isolation at E3.5 (Day 0) and after being cultured for 5 days (Day 5). Arrows point to inner cell 
mass, which is missing in Ect2-/- blastocysts. Arrowheads point to trophectoderm. (Data provided 
by Solski, Bultman, Cowley, and Van Dyke) 
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Table 2-2 Phenotypes and Genotype of Blastocyst Outgrowth Derived from Ect2 
intercrosses  
(Data provided by Solski, Bultman, Cowley, and Van Dyke) 
 +/+ +/- -/- ND 
Normala 27 58 0 12 
Abnormalb 3 2 6 6 
Unhatched 2 3 1 5 
Total 32 63 7 23 
ND, not determined. 
aSurvival and good outgrowth for trophectoderm and inner cell mass. 
bHatched, but inner cell mass failed to grow 
 
Normal development of Ect2+/- mice. Since Ect2-/- mice were embryonic 
lethal, we monitored Ect2+/- mice for haploinsufficiency. We compared Ect2+/- 
mice to their wild-type littermates at several stages of development. No changes 
in weight, gross appearance, or histology were found in Ect2+/- compared to wild-
type littermates at E15.5, 30 days, and one year (Figure 2-3A and data not 
shown). The lifespan of Ect2+/- mutant mice were then followed longitudinally. No 
differences in survival were observed between Ect2+/- mice and their wild-type 
littermates (Figure 2-3B). 
Given that we did not identify phenotypic differences between Ect2+/- mice 
and their wild-type littermates, we examined whether the reduced gene dosage 
of Ect2+/- heterozygotes resulted in a corresponding decreases in the level of 
Ect2 protein expression. We isolated mouse embryo fibroblasts (MEFs) at E15.5 
from both Ect2+/+ and Ect2+/- mice, and examined Ect2 protein levels (Figure 2-
3C). We found no significant differences in Ect2 protein expression between 
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Ect2+/- and Ect2+/+ MEFs, suggesting that Ect2+/- mice had equivalent levels of 
Ect2 protein compared to their wild-type littermates. 
 
Figure 2-3 Ect2+/- mice exhibit normal development and survival 
(A) Ect2+/- mice are similar in size and appearance as Ect2+/+ mice at E15.5, 30 days, and 1 year. 
(B) Ect2 protein expression in wild-type and ect2+/- MEFs. Cell lysates from the indicated cells 
were blotted with anti-Ect2 antibody and anti-β-actin to verify equivalent total protein loading. 
Densitometry scanning was used to quantitative the level of Ect2 expression, which were then 
normalized to the level of β-actin and then normalized to +/+ MEFs, with fold difference shown. 
(C) Ect2+/- mice have a similar survival age as Ect2+/+ mice. Mice were monitored for 25 months. 
(Data provided by Solski, Bultman, Cowley, Van Dyke, and Yeh) 
 
 
 50 
Ect2 deficiency results in multinucleated cells with altered 
morphology and impaired migration. As Ect2 deficiency was embryonic lethal, 
we isolated and immortalized MEFs from Ect2fl/fl and Ect2+/+ mice. These cells 
were then infected with recombinant adenovirus expressing Cre (Ad-Cre) to 
excise exon 8 of Ect2. An infection efficiency of 90-100% was achieved and this 
resulted in a complete loss of Ect2 expression (Figure 2-4A). Ad-Cre-infected 
Ect2fl/fl MEFs were much larger in size than their wild-type counterparts and 
appeared to have abundant nuclei and cytoplasm at 72 h post-infection. To 
examine this observation further, we sparsely plated Ad-Cre-infected MEFs on 
coverslips 24 h post-infection and allowed the cells to grow for 72 h. Using 
fluorescent microscopy, we found that Ad-Cre-infected Ect2fl/fl MEFs were large 
and multinucleated. Both Ect2fl/fl and Ect2+/+ MEFs appeared normal when 
infected with a control recombinant adenovirus expressing green fluorescent 
protein (Ad-GFP; Figure 2-4B and data not shown). We quantitated the 
difference in nucleation and found that Ad-Cre-infected MEFs which are Ect2-
dficient had a significantly higher percentage of multinucleated cells (~85%) 
compared to wild-type MEFs (<3%), suggesting that loss of Ect2 expression 
causes a defect in mitosis (Figure 2-4C). To further assess Ect2 expression in 
Ect2fl/fl MEFs infected with Ad-Cre, immunofluorescence of Ect2 was performed 
and the Ect2fl/fl MEFs infected with Ad-Cre showed a loss of specific Ect2 staining 
whereas the non-treated control showed clear Ect2 nuclear staining as expected 
(Figure 2-4D).  
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 The increase in multinucleation associated with loss of Ect2 expression 
was also quantified by cell cycle analysis, and the Ect2fl/fl MEFs showed a large 
increase in cells in G2/M phase when infected with Ad-Cre as compared to the 
Ad-GFP control virus and untreated MEFs (Figure 2-4E). Furthermore, Ad-Cre-
infection had no effect on wild-type MEFs indicating the specificity of the 
phenotype. Finally, the defect in cytokinesis could be rescued by infection with 
the FUGW lentivirus expression vector that encodes full length wild type human 
Ect2, demonstrating that impaired cytokinesis was due to loss of Ect2 expression 
(Figure 2-4A-E). 
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Figure 2-4 Loss of Ect2 expression results in an accumulation of multinucleated cells  
(A) Loss of Ect2 expression in Ad-Cre-infected MEFs. Western blot analysis with anti-Ect2 
antibody that recognizes the C-terminus of Ect2 was done to verify loss of Ect2 protein 
expression upon Cre-mediate excision of Ect2. Blot analysis with anti-β-actin antibody was done 
to verify equivalent total protein. NT, no treatment; Ad-Cre, infected with Cre adenovirus; Ad-
GFP, infected with control vector GFP adenovirus. (B) Fluorescent images of Ect2fl/fl MEFs 
ectopically expressing FUGW vector or expressing Ect2 and infected with Ad-GFP control vector 
or Ad-Cre adenovirus. Scale bar is 20 µm. Nuclei were stained with DAPI (blue) and F- actin with 
phalloidin (green) (C) Quantification of nuclei per cell in Ect2+/+, Ect2fl/fl vector, Ect2fl/fl MEFs with 
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no treatment (NT), adenovirus GFP (Ad-GFP), or adenovirus Cre (Ad-Cre). Cells were stained 
with a nuclear specific dye DAPI. Results are representative from one of three experiments. 
Nuclei per cell were counted for approximately 100 cells per field and five fields per condition. 
Standard error of the mean (SEM) is shown and were determined by the standard deviation 
divided by the square root of n = 5 different fields. (D) Immunofluorescence of Ect2 expression in 
Ect2fl/fl MEFs that were not treated (NT) or infected with Cre adenovirus (Ad-Cre). Green is 
endogenous Ect2 expression detected using an anti-Ect2 antibody. (E) Cell cycle profiles by flow 
cytometry of analysis of Ect2+/+, Ect2fl/fl vector (FUGW), Ect2fl/fl Ect2 (FUGW-Ect2). Abbreviations 
used are: MEFs with no treatment ,NT; control virus,Ad-GFP; Cre recombinase expressing virus, 
Ad-Cre.   
 
Since Ect2 is an activator of Rho GTPases and Rho GTPases regulate 
actin reorganization, we also evaluated the consequences of Ect2 loss on actin 
organization. Phalloidin staining of control and Ad-Cre-infected MEFs showed 
similar low levels of actin stress fibers, but there was a reduction in membrane 
ruffling (Figure 2-4B). Since Rho GTPases can regulate cell attachment and 
migration we also utilized time-lapse microscopy to monitor cell motility. Control 
Ad-GFP-infected MEFs exhibited high motility, whereas Cre-mediated loss of 
Ect2 caused a striking near complete loss of this activity.  
Rho GTPases cannot rescue the multinucleated phenotype caused 
by loss of Ect2. There is considerable evidence that suggests that the 
requirement for Ect2 during cytokinesis is for activation of RhoA at the central 
spindle and midbody to complete mitosis [65, 81]. However, there is also 
evidence that Ect2 activation of Cdc42 but not Rac1 is important for mitosis [83]. 
In contrast, a recent study determined that ectopic expression of constitutively 
activated Rac1 but not RhoA (or Cdc42) that rescued the loss of endogenous 
Ect2 to restore lung carcinoma cell anchorage-independent growth and invasion 
[38]. Thus, the specific Rho GTPase important for the role of Ect2 in cytokinesis 
remains to be elucidated. 
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To determine if a specific activated Rho GTPase could rescue the 
cytokinesis defect caused by the ablation of Ect2 expression, hemagglutinin (HA) 
epitope-tagged wild-type or constitutively active, GTPase-deficient mutants 
[RhoA(Q63L), Rac1(Q61L) and Cdc42(Q61L)] were each stably expressed in 
Ect2fl/fl MEFs prior to Cre expression (Figure 2-5A). Surprisingly, expression of 
wild-type or constitutively active GTPases failed to rescue the multinucleation 
phenotype associated with the loss of Ect2 expression (Figure 2-5B). Since fast 
cycling mutants with enhanced intrinsic nucleotide exchange activities may better 
model GTPase activation by a RhoGEF [87], we also ectopically expressed 
RhoA(F30L), Rac1(F28L) or Cdc42(F28L) in Ect2-depleted MEFs but no rescue 
of cytokinesis was seen. These negative results contrast with the ability of 
constitutively activated Rac1(Q61L) to rescue loss of cytoplasmic mislocalized 
Ect2 in lung cancer cells [38], and may indicate the requirement for a more 
precise temporal and spatial control of GTPase activity during normal cell 
cytokinesis.  
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Figure 2-5 Rho GTPases did not rescue the defect cytokinesis caused by loss of Ect2  
(A) Western blot analysis of Ect2fl/fl MEFs ectopically expressing HA-tagged RhoA, Rac1, and 
Cdc42 wild-type (WT) and constitutively active mutants of RhoA (Q63L point mutation) or Rac1 
and Cdc42 (Q61L). (B) Cell cycle profiles by flow cytometry of analysis of Ect2fl/fl MEFs 
ectopically expressing HA-tagged RhoA, Rac1, and Cdc42 wild-type (WT) and constitutively 
active GTPases with no treatment (NT), control virus (Ad-GFP) or Cre infection (Ad-Cre).  
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Discussion 
Despite the fact that Ect2 is one of at least 25 RhoGEFs that activate 
RhoA, observations made in cell culture studies and in Drosophila [29] and C. 
elegans [88] suggest an essential and unique role for this RhoGEF in cytokinesis 
and cell growth. To evaluate a function for Ect2 in normal mammalian cell 
physiology, we generated knockout mice. We found that an Ect2 deficiency 
caused early embryonic lethality and a complete loss of proliferation in vitro that 
was associated with impaired cytokinesis, altered cell morphology and 
suppressed cell migration. We conclude that Ect2 function is unique among all 83 
mammalian RhoGEFs in its essential requirement for cytokinesis. 
 Our studies provide the first analyses of mammalian Ect2 function in 
normal cells in vitro and in vivo. Previously, Ect2 function in vivo was evaluated in 
Drosophila and C. elegans invertebrate species. In Drosophila, loss of function of 
the Ect2 ortholog, pebble, resulted in embryonic lethality [29]. Homozygous 
pebble deficient mutant embryos at the end of embryogenesis contained fewer 
and larger cells with enlarged nuclei. The first 13 rapid syncytial nuclear divisions 
proceeded normally in pebble deficient embryos. Following cellularization, the 
postblastoderm nuclear divisions occurred (mitoses 14, 15 and 16), but 
cytokinesis was not observed, with multinucleated cells seen at cycle 15 mitoses. 
In C. elegans, RNA interference of Ect-2 caused sterility and embryonic lethality, 
in addition to reduced migration of embryonic P-cells [88]. However, there is 
evidence for a second mammalian Dbl family RhoGEF, GEF-H1, in regulation of 
cytokinesis[22] and no GEF-H1 orthologs are found in Drosophila or C. elegans. 
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Additionally, Ect2-independent cytokinesis has been described in some human 
cell types,[89]. Therefore, we anticipated the possibility that Ect2 may not be 
required for normal cell cytokinesis in vivo. However, our finding of embryonic 
lethality secondary to Ect2 deficiency is consistent with the essential role for this 
RhoGEF in normal cell cytokinesis. As Ect2 activates Rho GTPases that can be 
activated by other RhoGEFs, Ect2 must regulate Rho GTPases in a highly 
unique spatial and/or temporal pattern of activation that cannot be facilitated 
accurately by any other RhoGEF. 
Similar to our observations with an Ect2 deficiency, a MgcRacGAP 
deficiency also results in pre-implantation lethality [54]. MgcRacGAP is a 
component of central spindlin and facilitates Ect2 recruitment to the central 
spindle. siRNA depletion of MgcRacGAP phenocopies Ect2 loss and results in a 
cytokinesis defect in vitro [23, 25, 26, 90]. At E3.0-3.5, the MgcRacGAP 
deficiency caused formation of binucleated blastomeres, suggesting that 
MgcRacGAP is required for normal mitosis and cytokinesis in the pre-
implantation embryo. All homozygous mutant blastocysts failed to grow out in 
vitro. The similar developmental consequences of Ect2 or MgcRacGAP loss 
suggest that the Ect2 deficiency-induced embryonic lethality is a consequence of 
the role of Ect2 in cytokinesis. 
A recent study addressed a role for Ect2 in mouse oocyte meiosis in vitro 
and found that Ect2 depletion caused a block in the extrusion of the first polar 
body [91]. This observation suggests a much earlier requirement for Ect2 in 
development than suggested from our studies. This is likely due to the presence 
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of maternal Ect2 in the oocytes derived from Ect2-/+ intercrosses. The 
requirement for Ect2 in meiosis was found to be associated with RhoA and RhoA 
activation of its effector, the ROCK serine/threonine kinase. 
 In a majority of previous studies addressing the consequence of a specific 
RhoGEF deficiency for normal mouse development, while specific cellular 
defects have been identified, generally normal development and viability were 
retained [12]. These observations are consistent with the redundant functions of 
RhoGEFs, with 83 mammalian RhoGEFs regulating 14 Rho GTPases (six Rho 
GTPases are constitutively active and not believed to be regulated by RhoGEFs) 
[49]. While two Dbl RhoGEFs have been found to be essential for mouse 
development, because they possess additional non-RhoGEF catalytic functions, 
it is not clear that this is due to the loss of their RhoGEF activities. For example, 
a Sos1 deficiency leads to embryonic lethality [50, 92], but this is most likely due 
to the fact that Sos1 is also a RasGEF and key regulator of Ras activation by 
receptor tyrosine kinases. Deficiency in another Dbl RhoGEF, Trio, also causes 
embryonic lethality, with Trio-/- embryos dying between E15.5 and birth, or shortly 
thereafter [51]. However, Trio is multifunctional protein possessing two distinct 
DH-PH tandem domains, one active on RhoA and the second on Rac1, and 
additionally a protein serine/threonine kinase domain. Thus, whether the 
essential function of Trio in development is its two RhoGEF functions is not clear. 
In contrast to Sos1 and Trio, Ect2 has no other known catalytic function aside 
from its RhoGEF activity, although Ect2-interacting proteins may facilitate Ect2-
dependent, non RhoGEF-associated functions important for cytokinesis. 
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The role of Ect2 in cytokinesis has been attributed to recruitment of RhoA 
and localized RhoA activation at the central spindle complex [26, 39]. 
Additionally, our analyses of the isolated DH-PH domain fragment of Ect2 
identified activity for RhoA, the related RhoB and RhoC isoforms, but not for eight 
other Rho GTPase tested in vitro, including Rac1, Rac2 and Rac3 (data not 
shown). However, one study found that Ect2 was required for Cdc42 activation 
during mitosis [83] Furthermore, we and others found that constitutively activated 
N-terminally truncated Ect2 can activate RhoA, Rac1 and Cdc42 in vivo [43]. To 
determine the key Rho GTPase important for Ect2 regulation of cytokinesis, we 
determined if ectopic expression of constitutively activated RhoA, Rac1 or Cdc42 
could rescue the loss of endogenous Ect2 and restore proper cytokinesis. This 
approach was utilized recently to show that constitutively activated Rac1 alone 
could restore Ect2-dependent lung tumor cell growth [38]. Therefore, we were 
surprised that no one activated Rho GTPase was able to rescue the block in 
cytokinesis caused by Ect2 depletion. One possible explanation for this is that 
Ect2 may need to activate multiple Rho GTPases concurrently. Interestingly, 
consistent with our findings, activated RhoA orthologs did not rescue the Ect2 
deficiency-induced cytokinesis defect in Drosophila or C. elegans [88]. Another 
possible explanation may be that Ect2 activation of RhoA during cytokinesis is 
highly regulated spatially and temporally. Therefore constitutively activated RhoA 
may not accurately mimic this more precise regulation. Our ongoing evaluation of 
recombinant Ect2 Rho GTPase specificity found activity for only RhoA and 
related isoforms. Therefore, we favor the second possibility and our future 
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studies will address the importance of Ect2 subcellular localization in supporting 
cytokinesis. 
In addition to a cytokinesis defect, we also observed a defect in MEF cell 
morphology and migration. Ect2 loss in MEFs resulted in enlarged and flattened 
cells with increased cytoplasmic content. Whereas wild-type MEFs are highly 
motile, Ect2 loss resulted in a near complete loss of movement. Similar Ect2 
deficiency-associated defects were seen in normal cell migration in C. elegans 
and Drosophila [88, 93], and in tumor cell migration and invasion [38, 62]. 
However, these defects were associated with Rac and not RhoA activation. We 
observed that the Ect2 depletion-associated loss of MEF cell motility was 
associated with decreased membrane ruffling activity, an activity also associated 
with Rac activity. 
In summary, our studies provide the first analysis of Ect2 function in 
normal cells in vitro and in vivo, and we show that, despite the existence of 
multiple RhoGEFs, Ect2 plays an unique role in develop and progression through 
mitosis. Using our conditional mouse model, our ongoing studies will assess the 
consequences of Ect2 deficiency in adult tissue homeostasis and in tumor 
progression and maintenance. Furthermore, using MEFs with conditional Ect2 
loss, where we can rescue the cytokinesis defect by ectopic wild type Ect2 
expression, we will perform detailed structure-function analyses of Ect2 to 
delineate what aspects of Ect2 are essential for its unique role in maintenance of 
normal cell cytokinesis. 
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Chapter 3 Aberrant Ect2 expression and subcellular localization in 
colorectal cancer2  
Overview 
Ect2 is an activator of the RhoA small GTPase, is nuclear restricted in 
interphase cells and essential for normal cell cytokinesis. Ect2 was identified 
originally as potent oncoprotein when expressed in NIH 3T3 mouse fibroblasts. 
However, the mechanism of activation, N-terminal truncation and cytoplasmic 
mislocalization (designated ΔN-Ect2) was due to in vitro DNA manipulation and 
truncated Ect2 proteins have not been found in human cancer. We identified 
elevated full length Ect2 protein levels in CRC tumors and cell lines. Our 
immunohistochemistry analyses of a CRC tumor tissue microarray detected both 
cytoplasmic and nuclear Ect2, consistent with cytoplasmic mislocalization as a 
mechanism for Ect2 activation. However, unexpectedly, the ratio of cytoplasmic 
to nuclear expression correlated with improved patient survival. To address the 
importance of subcellular localization in CRC, we first determined that 
suppression of Ect2 expression impaired CRC cell line anchorage-independent 
growth and Matrigel invasion. Surprisingly, we found that ectopic expression of 
Ect2 variants with impaired nuclear localization did not rescue loss of 
endogenous Ect2 to restore anchorage-independent growth. Furthermore, the 
                                            
2 Chapter adapted from manuscript: “Aberrant Ect2 expression, subcellular localization and function in colorectal cancer” 
Cook, D.R., Kang, M., Martin, T.D., Galnako, J.A., Tran, J., Elizabeth, R.D, Statford, J.K., Temitope, K.O., Yeh, J., Robert, 
S.S., Der, C.J. 
 
 62 
cytoplasmic and constitutively activated ΔN-Ect2 mutant strongly impaired CRC 
growth. We conclude that nuclear Ect2 is important to support CRC growth, 
whereas cytoplasmic Ect2 activity is deleterious for CRC growth and may explain 
why truncated Ect2 proteins have not been found in human cancers. Finally, we 
determined that Ect2 nuclear localization is also essential to support normal cell 
cytokinesis. In summary, our results emphasize the critical role of precise 
subcellular localization in dictating Ect2 function in normal and neoplastic cells.  
Introduction 
Rho family small GTPases function as key signaling nodes that are 
activated by diverse extracellular stimuli that act on receptor tyrosine kinases, G 
protein-coupled receptors, integrins and other cell surface receptors. Once 
activated Rho GTPases engage downstream effectors that regulate cytoplasmic 
signaling networks that control actin organization, cell cycle progression and 
gene expression [6]. Therefore, it is not surprising that the aberrant activation of 
Rho GTPases has been implicated in cancer, neurological and developmental 
disorders and other human diseases [57, 94, 95]. However, in contrast to the 
related Ras small GTPases which are mutated in cancer and developmental 
disorders, Rho GTPases are infrequently mutated in disease. Instead, Rho 
GTPase activities are disrupted by indirect mechanisms [9]. 
The human Rho GTPase family is comprised of 20 members, with RhoA, 
Rac1 and Cdc42 the best-studied [49]. Rho GTPases function as GTP-GDP 
regulated binary on-off switches. Extracellular stimuli activate Rho-selective 
guanine nucleotide exchange factors (RhoGEFs) to promote GDP-GTP 
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exchange and formation of active Rho-GTP. Active Rho-GTP then binds multiple 
effectors, stimulating a cascade of cytoplasmic signaling networks. When the 
stimulus is terminated, Rho-selective GTPase activating proteins (RhoGAPs) 
accelerate the intrinsic GTP hydrolysis activity of Rho GTPases, returning the 
protein to the inactive GDP-bound state. Aberrant activation of RhoGEFs or loss-
of-function of RhoGAPs has been found in cancer, leading to persistent formation 
of the GTP-bound protein and stimulus-independent activation of effector 
signaling [9]. For example, we previously showed that the Rac-selective RhoGEF 
Tiam1 is an effector of mutationally activated Ras 
[96]. That mice deficient in Tiam1 or Rac1 show impaired mutant RAS-induced 
tumor formation demonstrates the important driver function of Rac activation in 
cancer development [97-99]. Similarly, we recently found that the Rac-selective 
RhoGEF P-Rex1 was upregulated by ERK mitogen-activated protein kinase 
signaling in melanoma and P-Rex1 deficient mice showed greatly reduced 
incidence of metastatic melanoma formation in an NRAS/INK4A-driven mouse 
model of melanoma [100]. A genome sequencing study identified frequent 
mutational activation of the related P-Rex2 protein in melanoma [101]. 
Dbl family proteins comprise the largest family of RhoGEFs (>70 human 
members) and their initial discovery as activated oncogenes provided the first 
evidence that aberrant Rho GTPase activation may drive cancer growth [12]. For 
example, Dbl, Ect2 and Vav RhoGEFs were detected in NIH 3T3 mouse 
fibroblast focus formation assays [10, 19, 102]. Their mechanism of activation 
involved N-terminal deletion of sequences upstream of their catalytic Dbl 
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homology domain. However, these activation events were determined to occur 
as a consequence of in vitro DNA manipulation rather than bona fide genetic 
events in cancer cells. Rather surprisingly, despite their potent transforming 
activities in NIH 3T3 cells, truncated RhoGEFs have not been found in human 
cancers [9]. Paradoxically, when implicated in cancer growth, only full length (FL) 
RhoGEFs have been found. Furthermore, while Ect2 is normally sequestered in 
the nucleus of interphase cells, they found that Ect2 was mislocalized and found 
in the cytoplasm due to phosphorylation by protein kinase C iota [38]. This 
mechanism of activation is functionally analogous to the N-terminally truncated 
and activated Ect2 (designated ΔN-Ect2) discovered initially in NIH 3T3 focus 
formation assays, where nuclear localization sequences (NLS) were lost in the 
truncated protein [19]. That disruption of the NLS motifs in FL Ect2 created a 
transforming protein when expressed in NIH 3T3 cells provided strong evidence 
that Ect2 oncogenic function is unmasked by mislocalization from the nucleus to 
the cytoplasm [36]. 
We identified ECT2 as a gene elevated in expression in human primary 
colorectal cancer (CRC). We determined that Ect2 protein levels were elevated in 
CRC tumor tissue and cell lines and that suppression of Ect2 expression 
impaired CRC cell line anchorage-independent growth and Matrigel invasion. 
Consistent with previous studies of Ect2 expression in other cancers, we also 
found Ect2 in the cytoplasm and nucleus. However, our immunohistochemistry 
staining of a CRC tumor microarray, unexpectedly, the ratio of cytoplasmic to 
nuclear Ect2 was associated with improved survival, suggesting that nuclear Ect2 
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may be important for cancer development and cytoplasmic Ect2 may be 
deleterious for cancer growth. To address this possibility, we determined that 
nuclear Ect2 was important to support CRC anchorage-independent growth and 
conversely that cytoplasmic, constitutively activated Ect2 was detrimental to CRC 
growth. Finally, we determined that CRC growth dependency on Ect2 was 
distinct from the role of Ect2 in cytokinesis, and unexpectedly, despite the 
absence of the nuclear envelope in cells undergoing cytokinesis, Ect2 support of 
cytokinesis required intact NLS motifs. In summary, our studies demonstrate a 
critical role for proper Ect2 subcellular localization in normal and neoplastic cell 
biology. 
Methods and Materials 
Gene array analysis: Gene array analysis was performed by RNA 
isolation and hybridization using Agilent human whole genome 4×44 K DNA 
microarrays (Agilent Technologies). RNA was extracted from macrodissected 
snap-frozen tumor samples using Allprep Kits (Qiagen) and quantified using 
nanodrop spectrophotometry (ThermoScientific). RNA quality was assessed with 
the use of the Bioanalyzer 2100 (Agilent Technologies); similar quality RNA was 
selected for hybridization using RNA integrity number and by inspection of the 
18S and 28S ribosomal RNA. One microgram of RNA was used as a template for 
DNA preparations and hybridized to Agilent 4×44 K whole human genome arrays 
(Agilent Technologies). cDNA was labeled with Cy5-dUTP and a reference 
control (Stratagene) was labeled with Cy3-dUTP using the Agilent (Agilent 
Technologies) low RNA input linear amplification kit and hybridized overnight at 
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65°C to Agilent 4×44 K whole human genome arrays (Agilent Technologies). 
Finally, arrays were washed and scanned using an Agilent scanner (Agilent 
Technologies). 
Oncomine Analyses: Sample data includes age, histology, microsatellite 
status, TNM stage, KRAS mutation status, sex, stage, and others. This dataset is 
a combination of Colon Adenocarcinoma [COAD] and Rectum Adenocarcinoma 
[READ] data from the TCGA data portal and consists of Level 2 (processed) 
data. Sample data includes age, histology, microsatellite status, TNM stage, 
KRAS and BRAF mutation status, sex, stage, and others. This dataset is a 
combination of Colon Adenocarcinoma [COAD] and Rectum Adenocarcinoma 
[READ] data from the TCGA data portal and consists of Level 3 data (segmented 
using CBS). The resulting segments were mapped to RefSeq gene coordinates 
as provided by UCSC (UCSC refGene, July 2009; hg18, NCBI 36.1, March 
2006). The samples were originally run on the Affymetrix SNP6 platform. 
Tumor samples and construction of tissue microarrays (TMAs): 
Cancer Care Outcomes Research and Surveillance Consortium 
(CanCORS) is a population-based cohort study. The study design of CanCORS 
has been described previously [103]. North Carolina CanCORS site enrolled 
newly diagnosed cases of CRC in North Carolina, encompassing both rural and 
urban areas. In addition to information collected by patient surveys and medical 
record review, the University of North Carolina site collected tissue blocks on 
consenting subjects. The study was approved by the human subjects committees 
at all participating institutions. TMAs were constructed from formalin-fixed, 
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paraffin-embedded colorectal tissues. Each microarray block included duplicate 
or triplicate cores of CRC and adjacent normal tissues from each patient. 29 
TMAs that included 441 patients were selected for staining. 
Immunohistochemistry (IHC) for ECT2: To validate the anti-Ect2 
polyclonal rabbit antibody (Millipore) for IHC, we utilized CRC cell lines and 
tissue. Positive controls included a colon cancer tissue and HT29 cells. HT29 
cells with ECT2 gene knockdown were used as negative controls. TMAs, positive 
and negative control slides were stained using anti-Ect2 antibody at 1:350 
dilution using Bond Antibody diluent (Leica Microsystems Inc.). Antigen was heat 
retrieved in citrate buffer, pH 6, for 30 min. The remainder of the staining was 
carried out using the Bond Polymer Refine Detection kit with the Bond 
Autostainer (Leica Microsystems Inc.) for the following times: primary antibody 6 
h, post-primary 8 min, polymer 8 min, peroxide block 5 min, 3,3-
diaminobenzidine 10 min, hematoxylin 7 min, and bluing 5 min.  
Scoring of TMAs: Prior to scoring, crypts and colorectal epithelium in 
each core on the TMAs were manually annotated to remove the lamina propria 
and non-epithelial cells. Only the annotated areas were scored. Scoring for Ect2 
expression was carried out using Cytoplasm algorithm in Imagescope (Aperio 
Inc.). Aperio Imagescope algorithms have been used for tumor tissue slide and 
TMA scoring and demonstrated good concordance with visual scoring in previous 
studies [104-106]. Further, the scoring was confirmed on a random sample of 
cores by visual inspection. Any cores with less than 300 epithelial cells, missing 
from falling off in the staining process, exhausted from prior sectioning, or cores 
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with staining artifact were excluded from analysis, which yielded 146 patients for 
analyses. Ect2 protein expression was measured by H-scores for nuclear or 
cytoplasmic staining (Cytoplasm Algorithm User’s Guide from Aperio). Briefly, H-
score is an intensity score derived from the average intensity of the staining of 
the corresponding area (cytoplasm or nucleus) or, in other words, cellular 
average. For example, there are three intensity thresholds (1+, weak, 2+, 
moderate and 3+, intense), and H-score equals sum of (% of cells with 1+ 
staining)+2*(% of cells with 2+ staining)+3*(% of cells with 3+ staining). This 
would yield a range of scores from minimum of 0 and maximum score of 300, 
where 300 would represent 100% of the cells are 3+ in intensity. In this study, H-
score and Ect2 scores represent the same, and these words were used 
interchangeably. 
Statistical analysis: ECT2 protein expressions were compared between 
tumor and normal tissues or between nuclear and cytoplasmic areas using paired 
t-test. Ect2 tumor scores were divided into tertiles, with cutoffs determined by 
Ect2 scores in normal tissues. To determine the association between patient 
characteristics and Ect2 tumor score tertiles, Kruskal-Wallis test was used for 2 
category variables, Spearman correlation for variables with more than 2 
categories (differentiation), and Wilcoxon rank test for continuous variable 
(overall survival). Cox proportional hazards models were used to calculate 
hazard ratios (HRs) and 95% confidence intervals (CIs) for mortality associated 
with continuous ECT2 scores. Multivariate models were fit to adjust for age (in 10 
year increments), stage (American Joint Committee on Cancer/ Union 
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Internationale Contre le Cancer stages 1, 2, 3, or 4), grade (well, moderate or 
poorly differentiated), location of CRC (proximal or distal), and chemotherapy 
(yes or no). All analyses were performed using SAS Version 9.2 (SAS Institute, 
Cary, NC). 
Cell lines and plasmids: CRC cell lines were obtained from ATCC and 
maintained in either DMEM-H or RPMI-1640 supplemented with 10% fetal calf 
serum, and frozen down to maintain limited passage history. Lentivirus vectors 
with shRNA sequences targeting human ECT2 and an expression vector for an 
shRNA resistant Ect2 cDNA expression vector kindly provided by Alan Fields 
(Mayo Clinic, Rochester, MN). The shRNA-resistant ECT2 cDNA sequence was 
used as a template for introduction of missense mutations or generation of 
truncations by the QuikChange site-directed mutagenesis kit (Stratagene). The 
wild type or mutant ECT2 cDNA sequences were subcloned into the pCDH EF1 
IRES puro lentiviral vector (Systems Biosciences) to encode an N-terminal 
hemagglutinin (HA) epitope tag. Immortalized mouse embryo fibroblasts (MEFs) 
derived from mouse embryos that harbor a conditional Ect2 floxed allele (Ect2fl/fl) 
[53]. Cre-mediated deletion results in a Δfloxed allele lacking exon 8 that is a null 
mutation based on the complete loss of Ect2 protein expression. Recombinant 
adenovirus expressing Cre recombinase (Ad-Cre) or green fluorescent protein 
(Ad-GFP) to control for effects due to adenovirus infection were used to induce 
loss of Ect2 expression (Gene Transfer Vector Core, University of Iowa). 
NIH 3T3 transformation Assays: NIH 3T3 mouse fibroblasts were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% Colorado 
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calf serum (Colorado Serum Company). Cells were transfected using 
lipofectamine 2000 (Invitrogen) in 6-well plates. Approximately 14-days post-
transfec- tion, the plates were stained with crystal violet, and the appearance of 
foci of transformed cells was quantified by visual inspection. 
Matrigel invasion assays: Real-time invasion assays where performed 
on the xCELLigance system (Roche). Similar to traditional Boyden chamber a 
CIM-Plate 16 (Roche) was used where the top of the trans-well was coated with 
Matrigel (BD Bioscience) and Matrigel and allowed to gel at 37°C, 5% CO2 for 
two h. After two h, cells where plated over the Matrigel in serum-free growth 
medium and complete growth medium supplement with 10% fetal calf serum was 
added to the bottom of the transwell as a chemoattractant. Invasive cells will 
migrate through the Matrigel then though the micropores of the CIM-Plate 16. 
These migrating cells are detected by the electronic sensing microelectrodes, 
producing changes in impedance, reported as cell index values. The 
xCELLigence system was set to collect impendence data every two min for at 
least 40 h [107, 108].  
Anchorage-independent growth assays: Anchorage-independent 
growth assays consisted of suspending cells in soft agar as described previously 
[109]. Briefly, cells were were resuspended in growth medium containing ~0.3% 
bacto agar(BD Biosciences) and the plated at 20,000 cells per well over a 0.6% 
bacto agar layer in 6-well plates. Cells were maintained at 37°C for 2-4 weeks. 
After this time, viable colonies were stained with the 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide viability stain for ~30 min at 37°C. Then 
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number of viable colonies of was quantified by counting the number of colonies in 
three wells per condition. Results are expressed as mean ± S.D.  
MTT proliferation assays: Cells were plated in 96-well plate at 1,000 
cells/well and allowed to grow at 37°C, 5% CO2, for 24-120 h. To asses growth 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (Sigma) was 
dissolved in PBS at 5 mg/ml and 20 uL of MTT solution was added to each well. 
The plates were incubated at 37°C, 5% CO2 for two h. After two h, the medium 
and MTT solution is removed and then the formazan product produced by living 
cells is dissolved by adding 100 uL of DMSO. After a few minutes at room 
temperature to ensure that all crystals were dissolved, the plates were read on 
ELX800 universal microplate reader (Bio-Tek instruments) at 570 nm. 
Flow Cytometry: Flow cytometry studies were performed on a Beckman-
Coulter (Dako) CyAn ADP. The analyzer is equipped forward and side scatter 
and 9 colors of fluorescence using 405 nm, 488 nm and 635 nm excitations.  
Cell Cycle: DNA content measurement identifies G0/G1-, S- and G2/M- 
phases of the cell cycle by propidium iodide staining. Cells were trypsinized, 
washed in PBS and then fixed in 70% ethanol and then stored at -20°C. The day 
prior to analysis the cells were washed in PBS and then stained with 0.5 ml of 
propidium iodine staining solution (1% Triton-X-100, 1 mg/ml PI, 100 mg/ml of 
RNAse A) overnight at 4°C. Data were collected on Beckman Coulter CyAn 
analyzer at at The UNC flow cytometry core facility and ModFit (Becton 
Dickinson) was used for cell cycle analysis. 
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Western blot analyses: To evaluate protein expression cell lysates were 
resolved by SDS-polyacrylamide gel electorphoresis followed by western blot 
analysis with antibodies that recognize Ect2 (Millipore), HA (Covance), β-actin 
(Sigma), lamin A/C (Cell Signaling), and HSP 90 (Upstate). 
Ect2 RhoGEF activity assays: The bacterially expressed glutathione S-
transferase fusion protein containing the nucleotide-free mutant of RhoA [GST-
RhoA(G17A)] was used as an affinity reagent to isolate active Ect2 expressed in 
cells were done as we have described in detail previously [110-112].Briefly, Ect2 
expressing cell lysates were normalized for equivalent total cellular protein and 
then incubated with 30 µg of purified GST-tagged RhoA(17A) bound to 
glutathione-sepharose beads for 60 min at 4°C. Samples were then washed with 
lysis buffer and processed for SDS-PAGE.  
Immunofluorescence: Twenty-four h after attachment, coverslips fixed 
with 2% paraformaldehyde in phosphate-buffered saline (PBS) for 10 min. The 
cells were stained for 5 min with 5 ng/ml 4',6-diamidino-2-phenylindole (DAPI) in 
PBS, washed 2-3 times with PBS and mounted with FluorSave (Calbiochem). 
The cells were visually analyzed for nuclei content on an Olympus BX61 upright 
fluorescence microscope. Images collected using Velocity (Perkin Elmer). To 
visualize polymerized F-actin, cells were stained with Alexa Fluor® 647 phalloidin 
(Invitrogen). 
Results 
Increased Ect2 gene and protein expression in CRC. To identify genes 
deregulated in expression in CRC, we performed gene microarray analyses on a 
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set of primary CRC and unmatched nontumor tissue. One gene found 
upregulated was ECT2 (Figure 3-1A). To determine whether Ect2 protein 
expression is elevated in CRC tumors, we performed blot analyses on a panel of 
matched normal, primary and metastatic CRC tissue. Increased Ect2 protein that 
comigrated with FL Ect2 was seen in six of eight primary CRC tumors when 
compared with normal (Figure 3-1B), with variable results seen with metastatic 
tumors. We also found high Ect2 protein expression in a majority of CRC cell 
lines (Figure 3-1C). Finally, adenoma tissue from the APC/Min mouse also 
exhibited elevated FL Ect2 protein levels (Figure 3-1D). When considered with 
APC mutation as the first genetic alteration in CRC tumor progression [69], and 
the consistent increase seen in primary CRC tumors, this
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Figure 3-1. Increased Ect2 RNA and protein expression in colorectal cancer  
A. Box plot of Ect2 mRNA expression from a microarray of 47 normal colon samples compared to 184 tumor samples. ***P-value = 4.784417e-16 
B. Ect2 protein expression in normal, primary, and metastatic tissues from 8 CRC patients. C. Elevated Ect2 protein expression in panel of CRC 
cell lines. D. Increased Ect2 protein in APC min mouse adenoma. E. Ect2 mRNA levels in 215 colorectal adenocarcinoma and 22 paired normal 
colorectal tissue samples were analyzed F. No significant ECT2 gene amplification in CRC. Data compiled from 436 CRC adenocarcinoma and 
351 paired normal blood and 94 paired normal CRC tissue samples were analyzed. 
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suggests that increased Ect2 expression is an early event in CRC tumor 
progression. 
Our identification of ECT2 by gene array analyses suggested that 
increased Ect2 protein expression was due to increased ECT2 gene 
transcription. To further address this possibility, we utilized Oncomine analyses 
and found increased ECT2 expression in both colon and rectal adenoma and 
adenocarcinoma from five published gene microarray datasets [113-117] as well 
as from the TGCA database (Figure 3-1E). In particular, the TGCA data set 
comprised of RNA data from 215 CRC adenocarcinoma and 22 paired normal 
CRC tissue and genomic DNA copy number data from 436 CRC and 351 paired 
normal blood and 94 paired normal colorectal tissue samples indicate that 
increased ECT2 expression is not due to gene amplification (http://tcga-
data.nci.nih.gov/tcga/) (Figure 3-1F). This result contrasts with lung cancer, 
where increased ECT2 gene expression was attributed to ECT2 gene 
amplification [38]. 
Increased ratio of Ect2 cytoplasmic-to-nuclear staining correlates 
with improved CRC patient survival. In addition to overexpression, the 
deregulated subcellular localization of normally nuclear Ect2 has also been 
described as a mechanism for causing aberrant Ect2 function in cancer [36, 38]. 
To determine if cytoplasmic mislocalization is associated with Ect2 in CRC, after 
validating an anti-Ect2 antibody for immunohistochemistry (IHC) analyses, we 
performed Ect2 expression analyses on a CRC tumor microarray. The results are 
presented for 146 patients that had Ect2 scores for normal, tumor or both as well 
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as information on overall survival and clinicopathologic characteristics. Shown in 
Figure 3-2A are representative stained tumor sections. Tumors displayed a range 
of staining, with the moderate to high levels seen in tumor but not adjacent 
nontumor tissue. 
 The overall Ect2 score (sum of nuclear and cytoplasmic scores) was 
higher in the tumor compared to the adjacent normal tissue (87.9 versus 72.5, 
respectively), but the difference was not statistically significant (p=0.09). Nuclear 
staining was more prevalent than cytoplasmic staining (51.1+3.6; average of 
tumor and normal nuclear scores + standard error) versus 29.1+2.6, respectively) 
(p <0.001). We also evaluated nuclear and cytoplasmic Ect2 protein expressions 
separately to determine the localization within each region. The tumor had higher 
Ect2 expression than the normal, for both cytoplasmic and nuclear sites (p=0.13 
nuclear, p=0.06 cytoplasmic) (Figure 3-2B). When the ratio of Ect2 cytoplasmic 
score over Ect2 nuclear score was compared between tumor and normal, the 
ratio was significantly higher in the tumor tissues (p=0.01) (Figure 3-2C).  
 Next we assessed the relationship between tertiles of Ect2 expression 
(low, medium and high) and clinicopathologic characteristics. There was a 
significant association between nuclear Ect2 expression and tumor grade. In 
particular, well-differentiated tumors tended to have low Ect2 nuclear expression, 
but as the grade increased to poorly differentiated tumors, Ect2 nuclear 
expression was increased (p=0.04 for trend) (Table 3-1). Males tended to have 
higher cytoplasmic to nuclear Ect2 score ratios compared to females who were 
more likely to have lower Ect2 ratios (Table 3-2). Tumors located in the distal 
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colon and rectum also had higher Ect2 ratios than proximal tumors, which tended 
to have low Ect2 ratios (Table 3-2). No statistically significant associations were 
found between cytoplasmic Ect2 scores and evaluated clinicopathologic 
characteristics. Furthermore, there were no statistically significant associations 
between nuclear Ect2 expression alone or cytoplasmic Ect2 expression alone 
and overall survival. However, we observed that Ect2 cytoplasmic to nuclear ratio 
showed a positive relationship. Overall survival improved with increasing 
cytoplasmic to nuclear expression ratio (p=0.001), suggesting that the site of 
localization of Ect2 either in the nucleus or cytoplasm may be a better determent 
of CRC prognosis (Figure 3-2D).  
Table 3-1 Associations between patient characteristics and tertiles of ECT2 scores for 
nuclear expression 
   N ECT2 low ECT2 medium ECT2 high P value 
Age, mean (SE) 139 66.1 (1.6) 67.0 (2.0) 65.1 2.1) 0.81 
Gender, n (%)      
   Male 77 24 (31) 26 (34) 27 (35) 0.54 
   Female 62 23 (37) 19 (31) 20 (32)  
Race, n (%)      
   White 107 34 (32) 34 (32) 39 (36) 0.38 
   Black 29 11 (38) 10 (34) 8 (28)  
Stage, n (%)      
   1+2 50 17 (34) 11 (22) 22 (44) 0.76 
   3+4 58 16 (28) 23 (40) 19 (33)  
Differentiation, n (%)      
   Well 6 4 (66) 1 (17) 1 (17) 0.04 
   Mod 81 26 (32) 25 (31) 30 (37)  
   Poor 18 3 (17) 6 (33) 9 (50)  
Location, n (%)      
   Proximal 46 15 (33) 14 (30) 17 (37) 0.62 
   Distal  56 18 (32) 22 (39) 16 (29)  
 
 To address if Ect2 expression correlates to patient characteristics leading 
to an increase in mortality, we employed Cox proportional hazards models. In the 
univariate model, a higher Ect2 cytoplasmic to nuclear ratio was significantly 
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associated with a lower risk of death in a piecewise manner: as the ratio 
increased by 0.5 increments, the risk of death decreased by 40%. However, 
increasing age (by 10 year increments), higher tumor stage than lower stages, 
and poor tumor grade were associated with increased risk of death. Even after 
adjustment for age, stage, differentiation, location of tumor and chemotherapy, a 
higher cytoplasmic to nuclear Ect2 ratio still demonstrated a reduced risk of dying 
that was statistically significant, suggesting that a high proportion of cytoplasmic 
Ect2 expression to nuclear expression may be a good prognostic marker in CRC. 
 
Table 3-2 Associations between patient characteristics and tertiles of ECT2 scores for the 
ratio of cytosolic to nuclear expression 
Characteristic N ECT2 low ECT2 medium ECT2 high P value 
Age, mean (SE) 139 67.8 (1.9) 67.0 (1.9) 63.5 (1.9) 0.25 
Gender, n (%)      
   Male 77 21 (27) 26 (34) 30 (39) 0.06 
   Female 62 26 (42) 19 (31) 17 (27)  
Race, n (%)      
   White 107 39 (36) 34 (32) 34 (32) 0.29 
   Black 29 8 (28) 9 (31) 12 (41)  
Stage, n (%)      
   1+2 50 12 (24) 16 (32) 22 (44) 0.77 
   3+4 58 14 (24) 21 (36) 23 (40)  
Differentiation, n (%)      
   Well 3 0 (0) 2 (33) 4 (67) 0.48 
   Mod 57 22 (27) 27 (33) 32 (40)  
   Poor 14 4 (22) 7 (39) 7 (39)  
Location, n (%)      
   Proximal 46 19 (41) 15 (33) 12 (26) 0.07 
   Distal  56 15 (27) 18 (32) 23 (41)  
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Figure 3-2 Increased ratio of cytosolic to nuclear Ect2 correlates with overall survival  
A. Increased Ect2 cytoplasmic and nuclear staining in CRC tumor. Representative examples of 
Ect2 staining by IHC for adjacent nontumor colorectal tissue and colorectal tumor tissues with 
weak, moderate, or strong intensity of Ect2 staining. Shown are 5x magnification in Aperio 
Imagescope. B. Ect2 expression in tumor cell cytoplasm and nuclear compartments. Ect2 score 
comparison between normal and tumor by nuclear and cytoplasmic locations. (P-value=0.13 
nuclear, P-value=0.06 cytoplasmic) C. Increased cytoplasmic-to-nuclear Ect2 staining in CRC 
tumor tissue. The ratio of Ect2 cytoplasmic score over ECT2 nuclear score was compared 
between tumor and normal, the ratio was significantly higher in the tumor tissues (P-value=0.01) 
D. Increased cytoplasmic-to-nuclear Ect2 staining correlates with improved CRC patient survival. 
Kaplan-Meier overall survival curve for the ratio of cytosolic to nuclear Ect2 (P-value=0.001)  
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Ect2 promotes CRC anchorage-independent growth and Matrigel 
invasion. To address a role for cytoplasmic and nuclear Ect2 in CRC biology, we 
first determined if Ect2 contributes to the aberrant growth properties of CRC cell 
lines. Utilizing two previously validated lentivirus-based ECT2 shRNA vectors 
[38], we established CRC cell lines with stable suppression of Ect2 protein 
expression (Figure 3-3A). Suppression of Ect2 expression did not significantly 
perturb anchorage-dependent cell proliferation (Figure 3-3B) or alter cell cycle 
progression (Figure 3-3C). However, a significant reduction in anchorage-
independent growth as determined by reduced colony formation in soft agar 
(Figure 3-3D) or invasion through Matrigel (Figure 3-3E) was seen. Thus, similar 
to lung cancer cells [38], endogenous Ect2 expression functions as a driver of 
CRC tumor cell growth and invasion independent of its role in regulation of 
cytokinesis.
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Figure 3-3 Ect2 is required for CRC cell line anchorage-independent growth and Matrigel invasion  
A. Western blot of the indicated CRC cell lines stably-infected with shRNA sequences targeting two different ECT2 sequences and non-targeting 
(NS) shRNA negative control. B. An MTT viability assay was used to monitor CRC cell line proliferation. C. Cell cycle analysis was done by DNA-
content staining with propidium iodide (PI) of the indicated CRC cell lines. Data shown are representative of three independent experiments. D. 
Suppression of Ect2 expression reduces CRC cell line anchorage-independent growth. Normalized graph of anchorage-independent growth as a 
function of Ect2 expression in CRC cell lines (n=3, P-value: * P<0.05, **P<0.01, *** P<0.001) E. Suppression of Ect2 expression reduces invasion 
in vitro. Real-time analyses of invasion (xCELLigence, Roche) of CRC cells through Matrigel. F. Immunofluorescence of endogenous Ect2 in 
green and actin in phalloidin; scale bars are 20 um  
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 Whereas in a recent analyses in lung cancer found that cytoplasmic Ect2 
was important for driving lung cancer growth [38], our IHC analyses found that 
increased nuclear Ect2 was associated with CRC progression and that 
cytoplasmic Ect2 may have a protective role. To address a role for nuclear 
localization in Ect2 support of CRC growth, we generated a set of HA epitope 
tagged structural/functional mutants of full length Ect2 (Figure 3-4A). We then 
utilized HT-29 cells to evaluate the structural requirements for Ect2 support of 
anchorage-independent growth. Suppression of endogenous Ect2 reduced 
colony formation and ectopic expression of wild type FL Ect2 at levels 
comparable or higher than endogenous restored colony formation (Figure 3-4B 
and C). In contrast, expression of a putative catalytic mutant with DH domain 
missense mutations did not restore colony formation, supporting the RhoGEF 
function of Ect2 in driving cancer growth. We next evaluated versions of full-
length variants of Ect2 with missense mutation of one (N1 or N2) or both (N3) 
NLS motifs. In contrast to endogenous Ect2 (Figure 3-2F) or ectopic expression 
of HA-Ect2 (Figure 3-4D), the NLS mutant proteins showed loss of nuclear 
staining and instead exhibited strong cytoplasmic staining (Figure 3-4D). In 
contrast to either ectopic WT or BRCT mutants of Ect2 that rescue colony 
formation, none of the NLS mutants where able to restore colony formation. 
These results suggest that the nuclear localization of Ect2 is required to support 
CRC growth. 
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Figure 3-4 Nuclear Ect2 is required to support anchorage-independent growth  
A. Diagram of Ect2 structural mutants showing missense or deletion mutations. B. Western blot of cells with stable shRNA suppression of 
endogenous Ect2 and ectopic expression of HA epitope-tagged Ect2 mutants in HT-29 cells. C, D. Analysis of CRC anchorage-independent 
growth. Representative experiment of BRCT and NLS Ect2 mutants (panel C) and then DH, PH and ΔC Ect2 mutants (panel D) compared to 
vector (HA) and WT Ect2 rescue. E. Immunofluorescence of HA-tagged Ect2 mutants in HT-29, where red is anti-HA and green is phalloidin; scale 
bars are 20 um F. Shown are phase-contrast bright field CRC cells infected with a lentiviral expression vector encoding ΔN-Ect2. F. Equivalent 
activation state of cytoplasmic and nuclear Ect2. Pulldown analyses using the nucleotide-free RhoA mutant that binds preferentially to activated 
RhoGEFs.  
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Figure 3-5 Cytoplasmic Ect2 causes morphologic and growth transformation of NIH 3T3 mouse fibroblasts.  
A. Ectopic expression of WT and mutant Ect2 in NIH 3T3 cells. Western blot analysis of NIH 3T3 expressing HA-tagged Ect2 mutants B, C. NLS 
mutants of Ect2 causes transformation of NIH 3T3 cells. Quantitation of focus forming activity (panel B) with photographs of representative fields 
of NIH 3T3 cultures (panel C). D. Immunofluorescence of HA epitope-tagged Ect2 mutants in NIH 3T3, where red is anti-HA and green is 
phalloidin; scale 20 um. 
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 We also assessed the role of other sequences and domains in Ect2-driven 
CRC growth. We previously found that the C-terminus of Ect2 was essential for 
the ability of ΔN-Ect2 to transform NIH 3T3 cells and deletion of this C-terminal 
sequence from FL Ect2 caused a partial reduction in its ability to restore colony 
formation (Figure 3-4B). We also found previously that mutation of the PH 
domain did not impair ΔN-Ect2 transforming activity and similar mutation of the 
PH domain did not reproducibly reduce the ability of FL Ect2 to restore colony 
formation. Thus, in contrast to other RhoGEFs, the PH domain does not appear 
to be critical for DH domain function. Finally, we also assessed the roles of the 
BRCT domains. Previous studies found that the BRCT domains can serve as 
autoinhibitory domains by associating with the DH-PH domains and preventing 
effective GEF catalytic activity [31]. Additionally, the BRCT domains may interact 
with phosphorylated proteins and regulate Ect2 recruitment to the central 
spindling complex during cytokinesis [77, 78]. Missense mutation of the 
conserved tryptophan (W) residue was shown previously to disrupt the structural 
integrity and function of the BRCT domain [31]. Interestingly, we found that the 
single B1 or B2 or tandem B3 BRCT mutant proteins were also mislocalized from 
the nucleus and showed enhanced cytoplasmic staining (Figure 3-4D). Despite 
mislocaliztion and reduced expression of the BRCT domain mutants (B1, B2, & 
B3), these mutants were still able to rescue colony formation (Figure 3-4C).  
 Altered subcellular localization from the nucleus to the cytoplasm may 
alter the intrinsic RhoGEF activity of Ect2 and contribute to the reduced ability of 
the NLS mutants. We previously described the use of dominant negative 
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nucleotide-free mutants of Rho GTPases that form nonproductive complex with 
RhoGEFs, as an affinity reagent to monitor the RhoGEF catalytic activity of cell 
expressed proteins [110-112]. Using this approach, we first validated that the 
recombinant GST-RhoA 17A fusion protein preferentially recognized wild type 
Ect2 relative to the GEF-dead DH domain mutant protein (Figure 3-4D). In 
contrast, both the N1 and N2 mutants were efficiently precipitated at a level 
comparable to wild type Ect2. Thus, the mislocalization of the NLS mutants did 
not impair their intrinsic RhoGEF catalytic function and the reduced colony 
formation activity may then be due to activation of different subcellular pools of 
Rho GTPases. 
Cytoplasmic localization is associated with Ect2 transformation of 
NIH 3T3 fibroblasts. Whereas the cytoplasmic, constitutively activated ΔN-Ect2 
truncated protein exhibits potent transforming activity when assayed in NIH 3T3 
fibroblasts, no truncated proteins have been described in human cancers. Thus, 
we speculated that perhaps ΔN-Ect2 may not be effective in supporting CRC 
growth. For these analyses we established NIH 3T3 cells stably expressing FL 
Ect2 wild type and mutant proteins (Figure 3-5A). We first verified that under our 
experimental conditions that ΔN-Ect2 is transforming and cytoplasmic 
mislocalized in NIH 3T3 cells (Figure 3-5B and C). Surprisingly, when we utilized 
a lentivirus-based cDNA expression vector (puromycin resistant) encoding ΔN-
Ect2, we failed to isolate puromycin-resistant stable populations of HT-29 cells 
that ectopically expressed this truncated protein. The cells that arose showed 
altered cellular morphology, elongated and poorly adherent, suggesting an 
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induction of apoptosis (Figure 3-4E). However, we were unable to verify the basis 
for this growth suppression since there was insufficient viable cells to perform a 
detailed analysis of the mechanism of growth inhibition.  
We also evaluated the transforming activity of full length Ect2 
structural/functional mutants. The transforming activity of the NLS mutants 
correlated with Ect2 mislocalization, with N1 and N3 mutants having increased 
cytosolic Ect2 and focus forming activity compared to N2 (Figure 3-5A and C). 
Unfortunately, while the BRCT mutants are also mislocalized (Figure 3-5D) to the 
cytosol these mutants did not express at the same levels of the NLS mutants and 
therefore the transformation ability is not comparable. However, some foci do 
arise from the BRCT mutants suggesting that these proteins may have 
transforming activity.  
Ect2 support of CRC growth is independent of its role in cytokinesis. 
Our finding that shRNA suppression of Ect2 did not reduce CRC anchorage-
dependent proliferation (Figure 3-2D) suggests that the impaired anchorage-
independent growth and invasion was not due simply to a defect in cytokinesis. 
Consistent with this possibility, our flow cytometry analysis did not find increased 
that is consistent with impaired cytokinesis (Figure 3-2E). This result contrasts 
with our previous finding that Ect2 depletion in mouse embryo fibroblasts (MEFs) 
caused significant accumulation of cells in G2/M. Taken together, these results 
suggest that Ect2 function in cytokinesis is mechanistically distinct from Ect2 
supported cancer growth. To address this question, we assessed the ability of 
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different Ect2 structural mutants to rescue the loss of endogenous Ect2 to 
support cytokinesis in MEFs. 
In contrast to anchorage independent growth in CRC cells, where the 
BRCT domains are dispensable for growth, cytokinesis requires intact BRCT 
domains. (Figure 3-6A and B) The Ect2 BRCT mutants expressed in MEFs also 
display mislocalization similar to CRC cells and NIH 3T3 fibroblasts (Figure 3-
6C). Additionally, the NLS mutants are also mislocalized and cannot rescue 
cytokinesis (Figure 3-6A-C). As expected, the GEF dead mutant (DH) cannot 
support cytokinesis Ect2, consistent with the requirement of Ect2 GEF activity for 
cytokinesis. Surprisingly, the C-terminal truncation and the PH domain missense 
mutant were able to rescue cytokinesis. Both of these mutants are properly 
localized to the cells nucleus during interphase and are able to bind dominate 
negative nucleotide-free RhoA, suggesting other functions of these domains are 
not necessary for normal function. Finally, we found that ectopic expression of 
the constitutively activated ΔN-Ect2 truncated protein, as we saw with NIH 3T3 
cells, was well tolerated by the Ect2fl/fl MEFs prior to Cre-mediated loss of Ect2. 
However, this variant did not support cytokinesis, most likely due to the loss of 
the NLS motifs and its cytosolic localization. 
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Figure 3-6 Nuclear localization is essential for Ect2 to support normal cell cytokinesis in mouse embryo fibroblasts 
A. Western blot of MEFs expressing HA-tagged Ect2 mutants. B. NLS and BRCT mutants fail to restore cytokinesis in cells deficient in 
endogenous Ect2 expression. Representative cell-cycle graphs, by DNA content with propidium iodide of MEFs expressing HA-tagged Ect2 
mutants then treated with either empty (control) or Cre (excise endogenous Ect2) adenovirus. C. Immunofluorescence of HA-tagged Ect2 mutants 
in MEFs, where red is anti-HA and green is phalloidin; scale bar is 20 um.  
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Discussion 
Conventional chemotherapy with cytotoxic drugs remains the foundation 
for first-line treatment of metastatic CRC, with limited advances in the 
development of signal transduction-targeted therapies for this cancer. To identify 
new molecular determinants for CRC diagnosis and therapy, we performed a 
microarray study and identified elevated ECT2 gene transcription in primary 
CRC. Since Ect2 was identified originally as an activated oncogene, we 
determined if Ect2 protein expression was altered and served a drive role in 
CRC. In particular, since previous studies in other cancers suggested that 
mislocalization of the normally nuclear restricted Ect2 into cytoplasm may 
facilitate aberrant Ect2 function [36, 38], we additionally addressed the role and 
function of nuclear and cytoplasmic Ect2 in CRC growth. We determined that 
Ect2 protein levels are altered in both expression levels and subcellular 
localization in CRC tumors and cell lines and we established a role for Ect2 in 
CRC cell line growth and invasion in vitro that is distinct from the involvement of 
Ect2 in cytokinesis. Unexpectedly, our IHC analyses of CRC tumors found that 
the cytoplasmic to nuclear ratio correlated with better patient survival. Consistent 
with this observation, we found that nuclear Ect2 is critical for driving CRC growth 
whereas cytoplasmic Ect2 activation was deleterious for CRC cell viability. Our 
findings also provide an explanation for why the originally discovered truncated 
and oncogenic Ect2 variants identified in mouse fibroblast transformation assays 
have not been found in human cancers. 
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Our determination that Ect2 is overexpressed in CRC, and that 
suppression of Ect2 expression impaired CRC cell line growth and invasion in 
vitro, expand the spectrum of human cancers where Ect2 may serve a driver 
function. Previously, Ect2 protein overexpression has been described for 
glioblastoma, lung and esophageal cancer [38, 61-63]. Our identification of ECT2 
RNA overexpression by microarray analyses and our Oncomine evaluation of 
existing microarray databases indicate that the increased levels of Ect2 protein is 
driven by increased gene transcription. Our Oncomine analyses of existing 
database information support our suggestion that this is caused by an increase in 
gene transcription, but not by the gene amplification which the causes Ect2 
overexpression in lung cancer [38]. A future direction of our studies will be to 
identify a mechanism for aberrant ECT2 gene overexpression in CRC. Our 
finding that Ect2 protein levels were elevated in adenoma tissue from the APC 
min mouse, together with Oncomine data that also showed increased ECT2 in 
patient adenoma tissue, argue that ECT2 upregulation likely occurs early in 
tumor progression. 
Ect2 was identified originally as an N-terminally truncated and 
constitutively activated protein (ΔN-Ect2), in the NIH 3T3 focus formation assays 
that discovered mutationally activated Ras proteins in human cancers [19]. A key 
basis for the transforming activity of ΔN-Ect2 was loss of NLS motifs, rendering 
the normally nuclear restricted Ect2 mislocalized into the cytoplasm. While no 
equivalent Ect2 truncation mutants have been described in human cancers, a 
recent study found that phosphorylation of full length Ect2 may force cytoplasmic 
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localization that may be critical for a role for Ect2 in driving lung cancer growth. 
To assess whether a mislocalization mechanism was also important for Ect2 
overexpression in CRC, we performed a detailed analysis of nuclear and 
cytoplasmic Ect2 in a CRC tumor tissue microarray. Although not significant, we 
observed an increase in Ect2 expression in both nuclear and cytoplasmic 
compartments compared to normal adjacent tissue. However, surprisingly, our 
analyses found that the ratio of cytoplasmic to nuclear Ect2 in CRC compared to 
normal adjacent tissue is statically significant (p<0.001) and an increased ratio 
correlates with increased overall survival. Our observations suggest that nuclear 
Ect2 is important for supporting CRC progression and/or growth, whereas 
cytoplasmic Ect2 may be beneficial for patient survival. This proposal contrasts 
with a recent study that speculated that cytoplasmic Ect2 was an important driver 
of lung cancer growth [38], suggesting cancer type differences in Ect2 driven 
cancer growth. In summary, our results emphasize the importance of assessing 
both Ect2 subcellular localization as well as overexpression in evaluating an 
association between aberrant Ect2 expresison and clinicopathologic 
characteristics. 
  Since the localization data from our IHC analyses was unexpected, we 
utilized CRC cell lines that we extablished to be Ect2-dependent for anchorage-
independent growth to evaluate a role for nuclear and cytoplasmic Ect2 in CRC 
growth. We utilized various structure/function Ect2 mutants to address the 
mechanism of Ect2 function in CRC compared to NIH 3T3 transformation and 
normal cell cytokinesis. Importantly, our studies are consistence our observation 
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that cytosolic Ect2 may be beneficial since the cytoplasm mislocalized Ect2 
mutants (N1-3) did not support CRC anchorage independent growth (Figure 3-
5C). However, BRCT Ect2 mutants were also cytoplasmic mislocalized but still 
had nuclear Ect2 suggesting that it is nuclear Ect2 that is required for growth. 
This observation also highlights the importance of the ratio of cytosolic to nuclear 
Ect2, suggesting that it is the relative proportion of Ect2 in these cellular 
compartments that determines growth. We also found that the transforming 
variant of Ect2 (ΔN-Ect2) cannot support CRC cell growth but instead it was 
highly deleterious to CRC growth in vitro. Thus, our mechanistic studies are 
consistent with our findings with CRC patient tumors, and support our hypothesis 
that cytoplasmic Ect2 is detrimental for cancer growth and also addresses why a 
constitutively activated truncated protein Ect2 has not been found in cancer. A 
future question will be to assess mechanisms that cause Ect2 mislocalization to 
the cytoplasm that may then be exploited pharmacologically to convert Ect2 from 
an oncogene into a tumor suppressor. Another issue will be determine whether 
Ect2 activates the same Rho family small GTPases in the cytoplasm and nucleus 
and whether the effectors activated by these GTPases are distinct. 
 Similar with observations in lung cancer [38], we demonstrate that loss of 
Ect2 in CRC cell lines does not cause a defect in cell proliferation, suggesting 
that the role of Ect2 in cancer is distinct with its role in normal cell cytokinesis. To 
address this question specifically we used Ect2 structure/function mutants to 
identify what domains are required for cytokinesis. We found that unlike CRC cell 
lines, MEFs required intact BRCT domains. Furthermore, the NLS mutants did 
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not support cytokinesis suggesting that proper localization is also required for 
Ect2 function in cytokinesis. This result was unexpected, since the nuclear 
envelope is absent during cytokinesis [24]. Perhaps nuclear sequestion of Ect2 is 
needed as the nuclear envelop reforms and cells complete cytokinesis and exit 
from mitosis. As expected, we showed that the GEF-dead Ect2 mutant DH does 
not support cytokinesis, demonstrating that Rho GTPase regulation is the basis 
for Ect2 function in cytokinesis. This is consistent with previous studies 
implication RhoA activation in Ect2-dependent cytokinesis [81]. In contrast, we 
found that mutation of the PH domain did not impair Ect2 support of cytokinesis, 
an unexpected finding since the PH domain is typically essential for proper DH 
domain function for other Dbl family RhoGEFs. Another surprising result was our 
determination that the C-terminal sequence following the tandem DH-PH domain 
is also dispensable for cytokinesis. Previously, we showed that this C-terminal 
sequence was necessary for ΔN-Ect2 transformation of NIH 3T3 cells, by 
dictating RhoGEF specificity in vitro [43]. More recently it was shown that Ect2 
protein levels during mitosis was regulated through APC/Cdh1 interaction with 
the C-teminus [46]. However, our results suggest that while the C-terminus of 
Ect2 may have functional roles it is not necessary to complete cell cycle. Normal 
cell cytokinesis is a highly regulated cell program that requires appropriate 
temporal and spatial signaling. Thus as expected, most of the Ect2 
structure/function mutants cannot support proper cytokinesis.  
In summary, our studies provide further evidence that Ect2, a protein 
essential for normal cell cytokinesis, when overexpressed and mislocalized in 
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cancer, can acquire a driver role in cancer by a mechanism independent of 
regulation of cytokinesis. Of the more than 70 Dbl family RhoGEFs, Ect2 together 
with the Vav and P-Rex RhoGEF isoforms comprise a small handful with 
significant roles in cancer. Of these RhoGEFs, whereas P-Rex and Vav are 
mainly activators of Rac, Ect2 is primarily an activator of RhoA. Thus, in addition 
to being only one of two Dbl RhoGEFs with nuclear localization and possessing 
domains not found on any other RhoGEF, Ect2 may also have an unusual role in 
human carcinogenesis. 
 96 
Chapter 4 Final thoughts and future directions 
Overview 
My dissertation research studies have addressed the roles and 
mechanisms by which the Ect2 RhoGEF regulates normal cell cytokinesis and 
tumor cell growth. The key findings from my studies are that (1) Ect2 is essential 
for development, most likely due to its critical role in normal cell cytokinesis, (2) 
Ect2 overexpression is a driver of CRC growth, (3) Ect2 may serve distinct 
nuclear and cytoplasmic functions in CRC growth, and finally, (4) the structural 
requirements for Ect2 are distinct for growth transformation of mouse fibroblasts 
and CRC, and for regulation of normal cell cytokinesis. My studies may also 
provide an explanation for a major paradox in the field, why the potently activated 
Dbl RhoGEFs identified initially as truncated proteins in NIH 3T3 transformation 
assays have not been found in human cancers. Below I discuss some key future 
questions and directions that have been prompted by my findings. 
Determining Nuclear Versus Cytosolic Ect2 Function 
The data from our recent structure-function studies of Ect2 in colorectal 
cancer suggests that nuclear and cytosolic Ect2 have different functions. 
Furthermore, the function of Ect2 in these individual compartments may be 
antagonistic and consistent with our TMA data from patients where a higher ratio 
of cytosolic compared to nuclear Ect2 correlated with increased overall survival.  
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To further validate our findings that cytosolic Ect2 could be negatively regulating 
anchorage-independent growth we could use nuclear transporter inhibitors, 
leptomycin A and/or B, in hopes that these are able to block the ability of Ect2 to 
become cytosolic. Leptomycin A and B are both potent inhibitors of nuclear 
export while the exact target of A is unknown B specifically blocks 
CRM1 (chromosomal region maintenance)/exportin 1 [118-120]. If these 
inhibitors are able to block cytosolic Ect2 we will investigate anchorage-
independent growth in the presence of nuclear transport inhibitors. If nuclear 
localization is the critical site for Ect2 driven CRC growth, then forced nuclear 
retention may actually enhance CRC growth. However, there since these 
inhibitors also block the transport of other proteins there could be significant off-
target effects. 
 The basis for cytoplasmic mislocalization is not clear. One simple 
explanation may be that mere overexpression saturates nuclear interactions, 
resulting in cytoplasmic “leakage”. One approach to evaluate this will be to use 
an inducible expression system where the levels of Ect2 expression could be 
titrated. There are many systems that would be amenable to such manipulation, 
for example the doxycycline-TET or the cumate inducible system by Systems 
Bioscience. In our current system, overexpression of WT Ect2 leads to an 
increase in cytosolic Ect2 and therefore may be the reason for both variable and 
reduced rescue in soft agar. In an inducible system we should be able to have a 
range of Ect2 expression such that the WT rescue could have no cytosolic Ect2 
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up to an expression level where there is additional Ect2 in the cytoplasm allowing 
us to see the effect of mislocalized Ect2 in anchorage-independent growth.  
Another approach to evaluate the role of subcellular localization can be to 
generate an Ect2 variant that is more strongly nuclear sequestered. To 
accomplish this, we could tag Ect2 with an additional stronger nuclear 
localization sequence (NLS) such as the SV40 large T-antigen sequence. 
However, if the mislocalization of Ect2 to the cytoplasm is dependent on the 
expression level, it suggests that it is excess of protein that is causing the 
mislocalization, then it is possible that this approach may not work.  
If Ect2 has distinct biological roles in the cytoplasm and nucleus, one 
logical basis for this is that each pool will activate a spatially distinct pool of 
RhoA, that then utilizes spatially distinct effectors. The impact of subcellular 
localization in determining effector utilization is seen in situations where Ras 
family GTPase subcellular localization is controlled by phosphorylation, leading 
to interactions with different effectors [6, 80, 121]. Currently there are limited 
methods that allow one to look at GTPase activity cellular compartments. 
However, genetically encoded biosensors would allow us investigate protein 
activity in live cells. Specifically, Dr. Kaus Hahn and colleagues have developed 
FRET (fluorescent or Förster resonance energy transfer) based biosensors of 
Rho GTPase [122, 123]. These biosensors allow one to investigate GTPase 
activity real-time with spatial resolution in live cells, allowing us to determine the 
location of GTPase activity to better the understand differences between nuclear 
versus cytosolic Ect2 downstream activity.  
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Although my pull down analyses with dominant negative RhoA suggests 
that Ect2 is equally active in the nucleus and cytoplasm, whether this approach 
accurately measures true catalytic activity is not known. Another possibility would 
be to design a FRET biosensor for Ect2. While there are no published reports of 
RhoGEF biosensors we know of groups taking this approach and while having an 
Ect2 biosensor would be a nice tool it would likely take considerable time to 
optimize. The ability for a biosensor to work depends on many factors, for 
instance FRET between fluorescent proteins depends on the relative dipole 
orientation of each fluoresce protein, for efficient energy exchange the dipoles 
need to be perpendicular to each other. The distance between the fluorescent 
proteins need to be less than 10 nm, for FRET to occur, and many biosensors 
require a linker region between the fluorescent protein and the protein of interest 
that usually needs to be optimized. Finally, since there is no know structure or 
models of Ect2 folding, no other RhoGEF biosensors to model from, designing an 
Ect2 biosensor would probably be time consuming but not impossible to achieve.  
Finally, as stated above, it is likely that Ect2 will interact with distinct 
proteins when in the nucleus and cytoplasm. This is particularly relevant since 
the BRCT domains can act as protein-protein interaction domains. To address 
this possibility, we could use a proteomic approach in tandem with a signaling 
pathway screen to identify nuclear from cytosolic Ect2 function in CRC. We will 
use mass spectrometry to identify novel binding partners of Ect2 in cytosolic 
versus nuclear cellular compartments by immunoprecipitating endogenous Ect2 
from these compartments. Use of Ect2 domain/deletion mutants can then be 
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used to map the site of interaction of these proteins. This would not only be the 
first complete proteomic analysis of Ect2 but also the first step in identifying 
proteins important in Ect2 function in nuclear or cytosolic compartments. To 
complement this approach we would do a screen for changes in pathways upon 
Ect2 induction. There are a variety of techniques or screens we could use to 
address changes in signaling pathways. We would do RNA sequencing, which 
provides quantifiable changes in all RNA: non-coding, coding and micro RNA 
[124]. Another approach we would employ is proteome phospho-arrays by R&D 
systems where we can look at changes in phosphorylation status of receptor 
tyrosine kinases (RTK) and other intracellular kinases by western blot. Identifying 
proteins that interact with Ect2 along with signaling pathways that change upon 
loss or activation of Ect2 will allow for a more detailed insight into Ect2 function.  
Inhibitors of Ect2-mediated exchange  
Our studies have validated Ect2 as a driver in CRC. However, RhoGEFs 
are not classically druggable proteins. However, druggabilty is based more on 
success, and protein kinases were once considered undruggable. There is 
currently limited evidence that perhaps RhoGEFs are druggable. We propose 
studies to identify small molecule inhibitors of Ect2, a Rho guanine because its 
importance in cancer is well validated: we showed Ect2 gene and/or protein 
overexpression in colon while there are other reports of its importance in lung, 
brain and pancreatic cancers. We have shown that Ect2 plays a role in tumor cell 
anchorage-independent growth and Matrigel invasion. If successful, our 
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establishment of the tractability of Ect2 as a target for inhibitors should support 
efforts to develop inhibitors against other GEFs involved in cancer.  
Our approach is similar to an already validated screen using a fluorescent 
polarization guanine nucleotide-binding assay [125]. The bases of this screen is 
GTP binding of Rho GTPases and fluorescent anisotropy. When Rho GTPases 
are in the inactive form, Rho is bound guanine diphosphate (GDP) but upon the 
binding of the Dbl homology/pleckstrin homology (DH/PH) domain of a RhoGEF 
(such as Ect2), a conformational change occurs in the switch regions of Rho, 
allowing the higher concentrated nucleotide GTP bind to Rho. We will use a 
fluorescently labeled nonhydrolysable form of the guanine nucleotide, GTPγS 
[126]. As a result, when Rho is bound to fluorescent GTP the rotation of the 
fluorescent signal is slowed and the polarized light will remain polarized while 
unbound fluorescent GTP rotates fast and will depolarize the light [127, 128].  
Potential mechanisms of inhibition of Ect2 stimulated Rho nucleotide 
binding, could include allosteric inhibition by drug binding to Rho, allosteric 
inhibition by drug binding to Ect2, competitive inhibition at the site of interaction 
between Ect2 and Rho, or finally competitive inhibition nucleotide binding to Rho.  
However, in contrast this the previous screen we will use both full-length 
and dominate active Ect2 protein and screen against activation of RhoA, Rac1, 
and Cdc42 GTPases since Ect2 has be implicated to active all of these GTPases. 
We expect some percentage of full-length Ect2 protein to be able to active 
GTPases based on our pervious pull-down results (Figure 3-4). However, since 
Ect2 is auto-inhibited [40] we will also screen using the active proportion of the 
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protein. Furthermore, we may identify unique inhibitors of Rho GTPases, which 
would allow us to further interrogate the individual pathways in Ect2 function.  
To validate any promising hits from the initial high throughput 
fluorescence-based screen, we will utilize a secondary GEF assay which 
monitors the incorporation of 3H-GTP into Rho [129]. The advantages of this 
secondary screen are one, there is no tag on the nucleotide (e.g., BODIPY-TR) 
that could potentially interfere with inhibitor binding, and two, it does not rely on a 
fluorescence signal which can sometimes be modulated by the specific chemical 
properties of the small molecule such as a cyclic structure. Together, the 
application of both assays will improve our chances to identify molecules that will 
be effective in our subsequent functional assays.  
Next, putative Ect2 inhibitor hits will counterscreen against other 
RhoGEFs that are selective for RhoA (Larg), Rac1(Tiam1, P-Rex1) and Cdc42 
(Asef) by using similar exchange assays. Those inhibitors that are selective for 
Ect2 but not the other RhoGEFs, will then evaluate in cell-based assays.  
We will determine if the Ect2 specific inhibitors can block dominate-active 
Ect2 driven transformation of NIH3T3 by formation of foci compared to WT Ect2, 
and Dbl as a positive control. We will test the ability of the Ect2 specific inhibitors 
to impair anchorage-independent growth of CRC cell lines compared to Ect2 
knockdown cells. We will also assess the ability of the inhibitors to block invasion 
on CRC cell lines through Matrigel. Our longer-term goal will be to develop Ect2 
inhibitors for evaluation in mouse models of colon cancer, in particular, in patient-
derived tumor xenograft models. 
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Mechanisms of Ect2-driven motility and invasion  
Our previous findings demonstrate that Ect2 has a role CRC cell 
invasiveness and there is evidence that Rho GTPases regulate different aspects 
of cell motility in cancer [57]. Additionally, we described a defect in the motility of 
MEFs upon Cre treatment resulting in the loss of Ect2; these cells exhibit a 
severe defect in random single cell migration [53]. Pebble, the Drosophila 
homolog of Ect2, is required for mesoderm migration via activation of RHO1. This 
activity was independent of the role of Pebble/Ect2 in cytokinesis [130]. 
Therefore it would be reasonable to investigate Ect2 function in cell motility and 
cancer cell invasiveness.  
 To address the mechanism of motility by Ect2 we can start with the 
analysis of our different Ect2 mutants produced previously (Figure 3-4). Using 
real-time invasion assays along with single cell motility assays of these Ect2 
mutants should elucidate the structural requirements for Ect2 function in motility 
and/or invasion. We predict that if Ect2 has a direct role in motility it would 
require its RhoGEF function, however, the location of Ect2 activity and its 
downstream activity would differ from that of Ect2 in cytokinesis. We predict that 
the RhoGEF function is critical for the role of Ect2 in motility due to the 
importance of Rho GTPase signaling in both migration and invasion. The 
subcellular localization of Ect2 may also play a role in the ability of Ect2 to 
promote motility. Therefore, the previous analysis of Ect2 function in the nucleus 
compared to cytosol will also assist in clarifying the mechanism of Ect2 function 
in motility and invasion.  
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Ect2 Mouse Model of Colorectal Cancer 
To address the role of Ect2 in a mouse model of colorectal cancer we 
need to first know if Ect2 is required for intestinal development, crypt formation, 
and maintenance. We propose crossing our Ect2fl/fl mouse containing a loxP site-
flanked Ect2 sequence with a villin-Cre mouse to selectively ablate Ect2 in the 
entire intestine. The villin-Cre (VC) mouse is a well-characterized model where 
the promoter from the villin gene drives the expression of Cre recombinase in 
100% of epithelial cells of the small and large intestines [131]. This would provide 
the first in vivo evaluation of Ect2 function in differentiated mammalian tissue.  
However, we may find that Ect2 is essential for intestinal development or 
maintenance of colonic tissue causing an inability to use the VC model to 
determine if Ect2 has a role in a mouse model of CRC. To overcome this 
potential limitation, we can use the VC-ERT mouse strain, which encodes an 
estrogen receptor-Cre fusion protein and therefore expresses a tamoxifen 
inducible form of villin-Cre [132]. In this model, no deletion of Ect2 would occur 
until the VC-ERT; Ect2fl/fl adult mice are treated by intraperitoneal injection of 
tamoxifen.  
Next we will use either the VC/Ect2fl/fl or VC-ERT/Ect2fl/fl mouse to cross 
with the with the APCmin/+ mouse to determine if Ect2 loss impairs colon 
tumorigenesis. The APCmin/+ mouse carries a truncation mutation at codon 850 
of the APC gene that causes multiple intestinal neoplasia (Min), typically resulting 
in ∼30 polyps in the small intestine per animal [133, 134]. This mouse model has 
been useful to identify proteins and mechanisms involved in colorectal cancer 
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tumorigenesis [73]. Additionally, our preliminary analyses found that Ect2 is 
overexpressed in adenomas from this model (Figure 3-1), indicating that it will be 
an ideal model for our studies investigating Ect2 in colorectal cancer.  
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